TWI653285B - Cured film forming composition, alignment material and retardation material - Google Patents
Cured film forming composition, alignment material and retardation material Download PDFInfo
- Publication number
- TWI653285B TWI653285B TW103129881A TW103129881A TWI653285B TW I653285 B TWI653285 B TW I653285B TW 103129881 A TW103129881 A TW 103129881A TW 103129881 A TW103129881 A TW 103129881A TW I653285 B TWI653285 B TW I653285B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- carbon atoms
- fluorine
- cured film
- alkyl group
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B5/00—Optical elements other than lenses
- G02B5/30—Polarising elements
- G02B5/3016—Polarising elements involving passive liquid crystal elements
Landscapes
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Liquid Crystal (AREA)
- Polarising Elements (AREA)
- Epoxy Resins (AREA)
- Manufacture Of Macromolecular Shaped Articles (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
本發明之課題係提供一種硬化膜形成組成物,其係用於提供具備優異之垂直配向性,即使在樹脂薄膜上亦可以高感度使聚合性液晶垂直配向之配向材、及使用該配向材之相位差材。 An object of the present invention is to provide a cured film forming composition for providing an alignment material having excellent vertical alignment properties and capable of vertically aligning a polymerizable liquid crystal with high sensitivity even on a resin film, and using the alignment material. Phase difference material.
本發明提供一種硬化膜形成組成物,其特徵係含有(A)使具有羧基及垂直配向性基之化合物之羧基對於側鏈或末端具有1個以上環氧基之聚合物之環氧基進行反應之聚合物、以及由(B)交聯劑及(C)酸觸媒所組成之群選出之至少一種化合物,進而提供一種配向材,其特徵係使用該組成物獲得,以及一種相位差材,其特徵係使用該組成物所得者。 The present invention provides a cured film forming composition comprising (A) reacting a carboxyl group of a compound having a carboxyl group and a vertical alignment group with an epoxy group of a polymer having one or more epoxy groups at a side chain or a terminal group. a polymer, and at least one compound selected from the group consisting of (B) a crosslinking agent and (C) an acid catalyst, thereby providing an alignment material obtained by using the composition, and a phase difference material, The characteristics are obtained by using the composition.
Description
本發明係關於適於使液晶分子垂直配向之垂直配向材之硬化膜形成組成物。尤其本發明係關於製作用以改善液晶顯示裝置(liquid crystal display:LCD),具體而言為填充具有正的介電異向性之液晶(△ε>0)之IPS液晶顯示裝置(In-plane Switching LCD;面內配向切換LCD)之視角特性而使用之+C板(positive C plate)有用之硬化膜形成組成物、配向材及相位差材。 The present invention relates to a cured film forming composition of a vertical alignment material suitable for vertically aligning liquid crystal molecules. In particular, the present invention relates to an IPS liquid crystal display device (In-plane) for improving a liquid crystal display (LCD), specifically, a liquid crystal (Δε>0) filled with positive dielectric anisotropy. Switching LCD; In-plane alignment switching LCD) The +C plate (positive C plate) is used to form a composition, a alignment material, and a phase difference material.
IPS-LCD具有由於不發生液晶分子之垂直方向之傾斜,故因視角造成之亮度變化/色變化較少之特徵,但列舉之弱點為對比度與亮度、應答速度不易提高。例如如專利文獻1所揭示,提案初期之IPS-LCD未使用視角之補償膜,因此未使用視野角之補償膜之IPS-LCD由於在傾斜角之暗狀態下之光漏相對較大,故有顯示低對比度值之缺點。 The IPS-LCD has a feature that the luminance change/color change due to the viewing angle is small because the tilt of the liquid crystal molecules does not occur in the vertical direction, but the weak points are that the contrast, the brightness, and the response speed are not easily improved. For example, as disclosed in Patent Document 1, the IPS-LCD in the initial stage of the proposal does not use the compensation film of the viewing angle, and therefore the IPS-LCD which does not use the compensation film of the viewing angle has a relatively large light leakage in the dark state of the tilt angle, so The disadvantage of displaying low contrast values.
專利文獻2中揭示使用+C板與+A板(positive A plate)之IPS-LCD補償膜。本文獻中,關於其所記載之液晶顯示元件,顯示以下構成。 Patent Document 2 discloses an IPS-LCD compensation film using a +C plate and a +A plate (positive A plate). In this document, the liquid crystal display element described above has the following configuration.
1)於可藉由對液晶層面施加平行電場之電極所供給之兩基板間夾持具有水平配向之液晶層。 1) A liquid crystal layer having a horizontal alignment is sandwiched between two substrates supplied by electrodes for applying a parallel electric field to the liquid crystal layer.
2)使一片以上之+A板與+C板夾持於兩偏光板中。 2) Clamp more than one +A plate and +C plate in the two polarizing plates.
3)+A板之主光軸垂直於液晶層之主光軸。 3) The main optical axis of the +A board is perpendicular to the main optical axis of the liquid crystal layer.
4)液晶層之相位差值RLC、+C板之相位差值R+C、+A板之相位差值R+A係以滿足下式之方式決定。 4) The liquid crystal layer retardation value R LC, + C plate retardation value of R + C, + A-plate retardation value of R + A of the system to satisfy the following formula decided.
RLC:R+C:R+A≒1:0.5:0.25 R LC :R +C :R +A ≒1:0.5:0.25
5)未顯示偏光板之保護膜厚度方向之相位差值相對於+A板與+C板之相位差值之關係(TAC、COP、PNB)。 5) The relationship between the phase difference in the thickness direction of the protective film of the polarizing plate and the phase difference between the +A plate and the +C plate (TAC, COP, PNB) is not shown.
且,基於提供藉由使傾斜角之暗狀態之光漏最小化而具有正面及傾斜角之高對比特性、低的色移(Color Shift)之IPS-LCD為目的,而揭示具有+A板與+C板之IPS-LCD(專利文獻3)。 Moreover, based on the provision of an IPS-LCD having a high contrast characteristic with a front side and a tilt angle and a low color shift by minimizing the light leakage of the dark state of the tilt angle, it is disclosed that the +A board is +C board IPS-LCD (Patent Document 3).
[專利文獻1]日本特開平2-256023號公報 [Patent Document 1] Japanese Patent Laid-Open No. Hei 2-256023
[專利文獻2]日本特開平11-133408號公報 [Patent Document 2] Japanese Patent Laid-Open No. Hei 11-133408
[專利文獻3]日本特開2009-122715號公報 [Patent Document 3] Japanese Patent Laid-Open Publication No. 2009-122715
[專利文獻4]日本特開2001-281669號公報 [Patent Document 4] Japanese Patent Laid-Open Publication No. 2001-281669
如以往所提案,+C板由於可補償在偏光板之視角較大時之光漏,故作為IPS-LCD之光學補償膜非常有用。然而,以往一般所知之藉由延伸處理之方法難以展現垂直配向(+C板)性。 As proposed in the past, the +C plate is very useful as an optical compensation film for IPS-LCD because it can compensate for light leakage when the viewing angle of the polarizing plate is large. However, it has been conventionally known that it is difficult to exhibit vertical alignment (+C plate) by the method of extension processing.
且,以往所提案之使用聚醯亞胺之垂直配向膜於膜製作中有必要使用N-甲基-2-吡咯啶酮等聚醯亞胺之溶劑。因此對玻璃基材雖無問題,但基材為薄膜時,會有形成配向膜時對基材造成損傷之問題。而且使用聚醯亞胺之垂直配向膜於必需在高溫下燒成時,會有薄膜基材不耐高溫之問題。 Further, in the conventional vertical alignment film using polyimine, it is necessary to use a solvent of a polyimine such as N-methyl-2-pyrrolidone for film production. Therefore, there is no problem with the glass substrate, but when the substrate is a film, there is a problem that the substrate is damaged when the alignment film is formed. Moreover, when a vertical alignment film using polyimine is required to be fired at a high temperature, there is a problem that the film substrate is not resistant to high temperatures.
再者,亦已提案藉由以具有長鏈烷基之矽烷偶合劑等直接處理基材,而形成垂直配向膜之方法,但基材表面不存在羥基時難以處理,而有基材受限之問題(專利文獻4) Further, a method of directly treating a substrate with a decane coupling agent having a long-chain alkyl group or the like to form a vertical alignment film has been proposed, but it is difficult to handle when a hydroxyl group is not present on the surface of the substrate, and the substrate is limited. Problem (Patent Document 4)
本發明係基於以上見解或檢討結果而完成者,其欲解決之課題係提供一種硬化膜形成組成物,其係用於提供具有優異之垂直配向性,同時具備光學補償膜所要求之透明性或溶劑耐性,且在樹脂薄膜上在低溫短時間之燒成條件亦安定且可使聚合性液晶垂直配向之配向材。 The present invention has been completed based on the above findings or review results, and the problem to be solved is to provide a cured film forming composition for providing excellent vertical alignment while having the transparency required for an optical compensation film or Solvent resistance, and the firing conditions on the resin film at a low temperature for a short period of time are also stable and the alignment of the polymerizable liquid crystal can be aligned.
且,本發明之另一目的係提供一種相位差 材,其係由上述硬化膜形成組成物而得,具備優異之垂直配向性,且可用於即使在樹脂薄膜上在低溫短時間之燒成條件亦安定且可使聚合性液晶垂直配向之配向材及使用其配向材形成之+C板。 Moreover, another object of the present invention is to provide a phase difference A material obtained by forming a composition of the above-mentioned cured film, having excellent vertical alignment property, and being used for an alignment material which is stable in a short-time firing condition on a resin film at a low temperature and which can vertically align a polymerizable liquid crystal. And a +C plate formed using the alignment material.
本發明人等為達成上述目的而重複積極檢討之結果,發現藉由選擇以側鏈具有長鏈烷基之丙烯酸共聚物作為基底之硬化膜形成材料,不管基材之種類均可形成具有優異垂直配向性之硬化膜,因而完成本發明。 As a result of repeating the positive review for achieving the above object, the present inventors have found that by selecting a cured film forming material having a long-chain alkyl group-containing acrylic copolymer as a base, it is possible to form an excellent vertical regardless of the type of the substrate. The oriented hardened film thus completes the present invention.
亦即,本發明之第1觀點係一種硬化膜形成組成物,其特徵係含有下列成分之硬化膜形成組成物:(A)使具有羧基及垂直配向性基之化合物之羧基對於側鏈或末端具有1個以上環氧基之聚合物之環氧基進行反應之聚合物、以及由(B)交聯劑及(C)酸觸媒所組成之群選出之至少一種化合物,且前述垂直配向性基係以下述式(1)表示之基,
(式[1]中,Y1表示單鍵,Y2表示單鍵或碳原子數1~15之伸烷基,或表示由苯環、環己烷環或雜環選出之2價環狀基,且前述環狀基上 之任意氫原子可經碳原子數1~3之烷基、碳原子數1~3之烷氧基、碳原子數1~3之含氟烷基、碳原子數1~3之含氟烷氧基或氟原子取代,Y3表示單鍵或碳原子數1~15之伸烷基,Y4表示單鍵,或表示由苯環、環己烷環或雜環選出之2價環狀基,或碳原子數17~30之具有類固醇骨架之2價有機基,且前述環狀基上之任意氫原子可經碳原子數1~3之烷基、碳原子數1~3之烷氧基、碳原子數1~3之含氟烷基、碳原子數1~3之含氟烷氧基或氟原子取代,Y5表示由苯環、環己烷環或雜環選出之2價環狀基,該等環狀基上之任意氫原子可經碳原子數1~3之烷基、碳原子數1~3之烷氧基、碳原子數1~3之含氟烷基、碳原子數1~3之含氟烷氧基或氟原子取代,n表示0~4之整數,n為2以上時,Y5可彼此相同亦可不同,Y6表示氫原子、碳原子數1~18之烷基、碳原子數1~18之含氟烷基、碳原子數1~18之烷氧基或碳原子數1~18之含氟烷氧基,Y2及Y3之伸烷基、以及環狀基上之取代基或Y6之烷基、含氟烷基、烷氧基及含氟烷氧基可為直鏈狀、分支狀或環狀之任一者或該等之組合,且Y2及Y3之伸烷基,以及Y6之烷基、含氟烷基、烷氧基及含氟烷氧基只要鍵結基彼此不相鄰則亦可以1至3個鍵結基中斷, 進而Y2、Y4或Y5表示2價之環狀基,或Y4表示具有類固醇骨架之2價有機基,或Y2或Y3表示伸烷基,或Y6表示烷基或含氟烷基時,該2價環狀基、該具有類固醇骨架之2價有機基、該伸烷基、該烷基及該含氟烷基亦可透過鍵結基與鄰接於該等之基鍵結,而且上述鍵結基係表示由-O-、-CH2O-、-CO-、-COO-、-OCO-、-NHCO-、-CONH-、-NH-CO-O-、-O-CO-NH-所組成之群選出之基,但,Y2至Y6各自表示之碳原子數1~15之伸烷基、苯環、環己烷環、雜環、具有類固醇骨架之2價有機基、碳原子數1~18之烷基、碳原子數1~18之含氟烷基、碳原子數1~18之烷氧基及碳原子數1~18之含氟烷氧基之碳原子數之合計為6~30)。 (In the formula [1], Y 1 represents a single bond, Y 2 represents a single bond or an alkylene group having 1 to 15 carbon atoms, or a divalent cyclic group selected from a benzene ring, a cyclohexane ring or a hetero ring. And any hydrogen atom on the above cyclic group may pass through an alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, a fluorine-containing alkyl group having 1 to 3 carbon atoms, and 1 carbon atom ~3 is substituted by a fluorine-containing alkoxy group or a fluorine atom, Y 3 represents a single bond or an alkylene group having 1 to 15 carbon atoms, Y 4 represents a single bond, or represents a benzene ring, a cyclohexane ring or a heterocyclic ring. a divalent cyclic group or a divalent organic group having a steroid skeleton having 17 to 30 carbon atoms, and any hydrogen atom on the above cyclic group may be an alkyl group having 1 to 3 carbon atoms and 1 carbon atom a alkoxy group of ~3, a fluorine-containing alkyl group having 1 to 3 carbon atoms, a fluorine-containing alkoxy group having 1 to 3 carbon atoms or a fluorine atom, and Y 5 represents a benzene ring, a cyclohexane ring or a heterocyclic ring a bivalent cyclic group selected, wherein any hydrogen atom on the cyclic group may pass through an alkyl group having 1 to 3 carbon atoms, an alkoxy group having 1 to 3 carbon atoms, or a fluorine atom having 1 to 3 carbon atoms. An alkyl group, a fluorine-containing alkoxy group having 1 to 3 carbon atoms or a fluorine atom, and n represents an integer of 0 to 4, n Is 2 or more, Y 5 may be the same or different from each other, Y 6 represents a hydrogen atom, an alkyl group having 1 to 18 carbon atoms, the fluorine-containing alkyl group, the number of carbon atoms of 1 to 18 carbon atoms, alkoxy of 1 to 18 oxygen a fluoroalkoxy group having 1 to 18 carbon atoms, an alkylene group of Y 2 and Y 3 , a substituent on the cyclic group or an alkyl group of Y 6 , a fluorine-containing alkyl group, an alkoxy group and the like The fluoroalkoxy group may be any of a linear chain, a branched chain or a cyclic group, or a combination thereof, and an alkylene group of Y 2 and Y 3 , and an alkyl group of Y 6 , a fluorine-containing alkyl group, an alkoxy group. The group and the fluorine-containing alkoxy group may be interrupted by 1 to 3 bonding groups as long as the bonding groups are not adjacent to each other, and further Y 2 , Y 4 or Y 5 represents a divalent cyclic group, or Y 4 represents a steroid. a divalent organic group of the skeleton, or Y 2 or Y 3 represents an alkylene group, or Y 6 represents an alkyl group or a fluorine-containing alkyl group, the divalent cyclic group, the divalent organic group having a steroid skeleton, and the extension The alkyl group, the alkyl group and the fluorine-containing alkyl group may also be bonded to the group adjacent to the bonding group, and the above bonding group is represented by -O-, -CH 2 O-, -CO-, Groups consisting of -COO-, -OCO-, -NHCO-, -CONH-, -NH-CO-O-, -O-CO-NH- Group, however, the number of carbon atoms, Y 2 to Y 6 each represent an extension of the alkyl group having 1 to 15, a benzene ring, a cyclohexane ring, a heterocyclic ring, a divalent organic group having a steroid skeleton of carbon atoms of 1 to 18 The total number of carbon atoms of the alkyl group, the fluorine-containing alkyl group having 1 to 18 carbon atoms, the alkoxy group having 1 to 18 carbon atoms, and the fluorine-containing alkoxy group having 1 to 18 carbon atoms is 6 to 30).
第2觀點係關於第1觀點所記載之硬化膜形成組成物,其中前述側鏈或末端具有1個以上環氧基之聚合物為主鏈上具有環構造之數平均分子量300至20,000之聚合物。 The cured film formation composition according to the first aspect, wherein the polymer having one or more epoxy groups in the side chain or the terminal has a number average molecular weight of 300 to 20,000 having a ring structure on the main chain. .
第3觀點係關於第1觀點或第2觀點所記載之硬化膜形成組成物,其中前述側鏈或末端具有1個以上環氧基之聚合物係由雙酚A型環氧樹脂、雙酚F型環氧樹脂、酚酚醛清漆型環氧樹脂、甲酚酚醛清漆型環氧樹脂、雙酚A酚醛清漆型環氧樹脂及多元醇之1,2-環氧基-4-(2-環氧乙基)環己烷加成物所組成之群選出之任一種聚合物。 The third aspect is the cured film forming composition according to the first aspect or the second aspect, wherein the side chain or the polymer having one or more epoxy groups at the terminal is a bisphenol A type epoxy resin or a bisphenol F. Type epoxy resin, phenol novolak type epoxy resin, cresol novolak type epoxy resin, bisphenol A novolak type epoxy resin and polyol 1,2-epoxy-4-(2-epoxy) Any polymer selected from the group consisting of ethyl)cyclohexane adducts.
第4觀點係有關第1觀點至第3觀點中任一項所記載 之硬化膜形成組成物,其中(B)成分之交聯劑為具有羥甲基或烷氧基甲基之交聯劑。 The fourth viewpoint is described in any one of the first to third aspects. The cured film forms a composition in which the crosslinking agent of the component (B) is a crosslinking agent having a methylol group or an alkoxymethyl group.
第5觀點係關於第1觀點至第4觀點中任一項所記載之硬化膜形成組成物,其中基於(A)成分100質量份,含有1質量份~100質量份之(B)成分。 The cured film forming composition according to any one of the first aspect to the fourth aspect, wherein the component (B) is contained in an amount of from 1 part by mass to 100 parts by mass based on 100 parts by mass of the component (A).
第6觀點係關於第1觀點至第5觀點中任一項所記載之硬化膜形成組成物,其中基於(A)成分100質量份,含有0.01質量份~20質量份之(C)成分。 The cured film formation composition according to any one of the first aspect to the fifth aspect, wherein the component (C) is contained in an amount of from 0.01 part by mass to 20 parts by mass based on 100 parts by mass of the component (A).
第7觀點係一種配向材,其特徵係使第1觀點至第6觀點中任一項所記載之硬化膜形成組成物硬化而得。 The seventh aspect is a aligning material obtained by curing the cured film forming composition according to any one of the first aspect to the sixth aspect.
第8觀點係一種相位差材,其特徵係使用由第1觀點至第6觀點中任一項所記載之硬化膜形成組成物而得之硬化膜所形成。 The eighth aspect is a phase difference material which is formed by using a cured film obtained by forming a composition of the cured film described in any one of the first aspect to the sixth aspect.
依據本發明之第1樣態,可提供一種硬化膜形成組成物,其可用於提供具備優異之垂直配向性,即使在樹脂膜上在低溫短時間之燒成條件亦安定且可使聚合性液晶垂直配向之配向材。 According to the first aspect of the present invention, it is possible to provide a cured film forming composition which can be used to provide excellent vertical alignment, which can be stabilized even at a low temperature for a short time on a resin film, and can be made of a polymerizable liquid crystal. Vertical alignment of the alignment material.
依據本發明之第2樣態,可提供一種具備優異之垂直配向性,在低溫短時間之燒成條件下安定且可使聚合性液晶垂直配向之配向材。 According to the second aspect of the present invention, it is possible to provide an alignment material which has excellent vertical alignment properties and which is stable under low-temperature firing conditions and which can vertically align the polymerizable liquid crystal.
依據本發明之第3樣態,可提供一種即使在樹脂膜上仍可以高效率形成之高透明且具有高的耐溶劑性 之相位差材。 According to the third aspect of the present invention, it is possible to provide high transparency and high solvent resistance which can be formed with high efficiency even on a resin film. Phase difference material.
本發明之硬化膜形成組成物含有(A)成分的使具有羧基及垂直配向性基之化合物之羧基對於側鏈或末端具有1個以上環氧基之聚合物之環氧基進行反應之聚合物、以及由(B)成分的交聯劑及(C)成分的酸觸媒所組成之群選出之至少一種化合物。本發明之硬化膜形成組成物除上述(A)成分、(B)成分、(C)成分以外,只要不損及本發明之效果,亦可含有其他添加劑。 The cured film of the present invention comprises a polymer having a composition in which the carboxyl group of the compound having a carboxyl group and a vertical alignment group is reacted with an epoxy group of a polymer having a carboxyl group and a vertical alignment group as a side chain or a polymer having one or more epoxy groups at the terminal. And at least one compound selected from the group consisting of a crosslinking agent of the component (B) and an acid catalyst of the component (C). The cured film forming composition of the present invention may contain other additives in addition to the above components (A), (B) and (C) as long as the effects of the present invention are not impaired.
以下,詳細說明各成分。 Hereinafter, each component will be described in detail.
本發明之硬化膜形成組成物中含有之(A)成分係使具有羧基及垂直配向性基之化合物之羧基對於側鏈或末端具有1個以上環氧基之聚合物之環氧基進行反應之聚合物。又,以下說明書中,(A)成分之聚合物亦稱為“垂直配向聚合物”。 The component (A) contained in the cured film formation composition of the present invention reacts a carboxyl group of a compound having a carboxyl group and a vertical alignment group with an epoxy group of a polymer having one or more epoxy groups at a side chain or a terminal. polymer. Further, in the following description, the polymer of the component (A) is also referred to as "vertical alignment polymer".
側鏈或末端具有1個以上環氧基之聚合物可使用具有環氧基之加成聚合性單體藉由加成聚合予以製造。或者,側鏈或末端具有1個以上環氧基之聚合物可藉由具有羥基酸基之高分子化合物與表氯醇、縮水甘油基甲 苯磺酸酯等之具有環氧基之化合物反應而製造。 A polymer having one or more epoxy groups in a side chain or a terminal can be produced by addition polymerization using an addition polymerizable monomer having an epoxy group. Alternatively, a polymer having one or more epoxy groups in a side chain or a terminal may be a polymer compound having a hydroxy acid group and epichlorohydrin, glycidyl group It is produced by reacting a compound having an epoxy group such as a benzenesulfonate.
側鏈或末端具有1個以上環氧基之聚合物之具體例列舉為例如聚甲基丙烯酸縮水甘油酯、甲基丙烯酸縮水甘油酯共聚物、聚(甲基丙烯酸3,4-環氧基環己基甲酯)、甲基丙烯酸3,4-環氧基環己基甲酯共聚物、雙酚A型環氧樹脂、雙酚F環氧樹脂、酚酚醛清漆型環氧樹脂、甲酚酚醛清漆型環氧樹脂、雙酚A酚醛清漆型環氧樹脂、三羥甲基丙烷之1,2-環氧基-4-(2-環氧乙基)環己烷加成物等。 Specific examples of the polymer having one or more epoxy groups in the side chain or the terminal are exemplified by, for example, polyglycidyl methacrylate, glycidyl methacrylate copolymer, and poly(3,4-epoxy ring of methacrylic acid). Hexylmethyl ester), 3,4-epoxycyclohexylmethyl methacrylate copolymer, bisphenol A epoxy resin, bisphenol F epoxy resin, phenol novolak epoxy resin, cresol novolac type Epoxy resin, bisphenol A novolac type epoxy resin, trimethylolpropane 1,2-epoxy-4-(2-epoxyethyl)cyclohexane adduct, and the like.
該等側鏈或末端具有1個以上環氧基之聚合物中,以主鏈上具有環構造之聚合物較佳,具體而言,基於提高液晶之塗佈性之觀點而言,以雙酚A型環氧樹脂、雙酚F環氧樹脂、酚酚醛清漆型環氧樹脂、甲酚酚醛清漆型環氧樹脂、雙酚A酚醛清漆型環氧樹脂、多元醇之1,2-環氧基-4-(2-環氧乙基)環己烷加成物等較佳。 Among the polymers having one or more epoxy groups at the side chain or terminal, a polymer having a ring structure in the main chain is preferred, and specifically, bisphenol is used in view of improving the coatability of the liquid crystal. A type epoxy resin, bisphenol F epoxy resin, phenol novolak type epoxy resin, cresol novolak type epoxy resin, bisphenol A novolac type epoxy resin, polyol 1,2-epoxy group A -4-(2-epoxyethyl)cyclohexane adduct or the like is preferred.
該等側鏈或末端具有1個以上環氧基之聚合物之分子量,以聚苯乙烯換算數平均分子量(以下稱為數平均分子量)較好為300至20,000。較好為400~10,000,更好為500~8,000者。 The molecular weight of the polymer having one or more epoxy groups at the side chain or terminal is preferably from 300 to 20,000 in terms of polystyrene-equivalent number average molecular weight (hereinafter referred to as number average molecular weight). It is preferably from 400 to 10,000, more preferably from 500 to 8,000.
上述側鏈或末端具有1個以上環氧基之聚合物可適當地使用市售品,至於具體例,雙酚A型環氧樹脂可列舉為jER1001、jER1002、jER1003、jER1004、jER1055、jER1007、jER1009、jER1010、jER834、jER828(以上為三菱化學(股)製)等,雙酚F型環氧樹脂可列舉為jER806、jER807(以上為三菱化學(股)製 造)等,酚酚醛清漆型環氧樹脂可列舉為jER152、jER154(以上為三菱化學(股)製)、EPPN201、EPPN202(以上為日本化藥(股)製),甲酚酚醛清漆型樹脂可舉例為ECN-1299(旭化成(股)製)、EOCN-102、EOCN-103S、EOCN-104S、EOCN-1020、EOCN-1025、EOCN-1027(以上為日本化藥(股)製)、jER80S75(三菱化學(股)製)等,雙酚A酚醛清漆型環氧樹脂可列舉為jER157S70(三菱化學(股)製)等,多元醇之1,2-環氧基-4-(2-環氧乙基)環己烷加成物可列舉為EHPE-3150(Daicel(股)製)等。 A commercially available product may be suitably used as the polymer having one or more epoxy groups at the side chain or the terminal. Specific examples of the bisphenol A type epoxy resin may be listed as jER1001, jER1002, jER1003, jER1004, jER1055, jER1007, and jER1009. , jER1010, jER834, jER828 (the above is Mitsubishi Chemical Co., Ltd.), etc., bisphenol F type epoxy resin can be listed as jER806, jER807 (above is Mitsubishi Chemical Corporation) Manufacture of phenol novolac type epoxy resin, such as jER152, jER154 (above is Mitsubishi Chemical Co., Ltd.), EPPN201, EPPN202 (above, manufactured by Nippon Kayaku Co., Ltd.), cresol novolac type resin Examples are ECN-1299 (Asahi Kasei Co., Ltd.), EOCN-102, EOCN-103S, EOCN-104S, EOCN-1020, EOCN-1025, EOCN-1027 (above is Nippon Chemical Co., Ltd.), jER80S75 ( Mitsubishi Chemical Co., Ltd., etc., bisphenol A novolac type epoxy resin can be exemplified by jER157S70 (manufactured by Mitsubishi Chemical Corporation), etc., 1,2-epoxy-4-(2-epoxy) of polyol The ethylenyl cyclohexane adduct is exemplified by EHPE-3150 (manufactured by Daicel Co., Ltd.).
本說明書中,所謂垂直配向性基係表示例如包含碳原子數為6~20左右之烴基之基,具體係指以後述之式[1]表示之基。 In the present specification, the vertical alignment group means a group containing a hydrocarbon group having a carbon number of about 6 to 20, and specifically means a group represented by the formula [1] described later.
據此,作為具有羧基及垂直配向性基之化合物,列舉為例如具有羧基與碳原子數6~20左右之烴基之化合物。 Thus, examples of the compound having a carboxyl group and a vertical alignment group include a compound having a carboxyl group and a hydrocarbon group having about 6 to 20 carbon atoms.
碳原子數6~20之烴基列舉為直鏈狀、分支狀或環狀之碳原子數6~20之烷基或含芳香族基之碳原子數6~20之烴基。 The hydrocarbon group having 6 to 20 carbon atoms is exemplified by a linear, branched or cyclic alkyl group having 6 to 20 carbon atoms or a hydrocarbon group having 6 to 20 carbon atoms having an aromatic group.
垂直配向性基更具體為以下述式[1]表示之基。 The vertical alignment group is more specifically a group represented by the following formula [1].
式[1]中,Y1表示單鍵。 In the formula [1], Y 1 represents a single bond.
式[1]中,Y2表示單鍵或碳原子數1~15之伸 烷基。 In the formula [1], Y 2 represents a single bond or an alkylene group having 1 to 15 carbon atoms.
且Y2列舉由苯環、環己烷環或雜環選出之2價環狀基,該等環狀基上之任意氫原子可經碳原子數1~3之烷基、碳原子數1~3之烷氧基、碳原子數1~3之含氟烷基、碳原子數1~3之含氟烷氧基或氟原子取代。 And Y 2 exemplifies a divalent cyclic group selected from a benzene ring, a cyclohexane ring or a hetero ring, and any hydrogen atom on the ring group may pass through an alkyl group having 1 to 3 carbon atoms and 1 to 1 carbon atom. 3 alkoxy group, fluorine-containing alkyl group having 1 to 3 carbon atoms, fluorine-containing alkoxy group having 1 to 3 carbon atoms or fluorine atom.
上述雜環為吡咯環、咪唑環、噁唑環、噻唑環、吡唑環、吡啶環、嘧啶環、喹啉環、吡唑啉環、異喹啉環、咔唑環、嘌呤環、噻二唑環、嗒嗪環、吡唑啉環、三嗪環、吡唑嗪環、三唑環、哌啶環、苯并咪唑環、噌啉環、菲繞啉環、吲哚環、喹喔啉環、苯并噻唑環、吩噻嗪環、噁二唑環、吖啶環等,更好為吡咯環、咪唑環、吡唑環、吡啶環、嘧啶環、吡唑啉環、咔唑環、嗒嗪環、吡唑啉環、三嗪環、吡唑嗪環、三唑環、哌啶環、苯并咪唑環。 The above heterocyclic ring is a pyrrole ring, an imidazole ring, an oxazole ring, a thiazole ring, a pyrazole ring, a pyridine ring, a pyrimidine ring, a quinoline ring, a pyrazoline ring, an isoquinoline ring, an oxazole ring, an anthracene ring, and a thiazide. Oxazole ring, pyridazine ring, pyrazoline ring, triazine ring, pyrazosin ring, triazole ring, piperidine ring, benzimidazole ring, porphyrin ring, phenanthroline ring, anthracene ring, quinoxaline a ring, a benzothiazole ring, a phenothiazine ring, an oxadiazole ring, an acridine ring, etc., more preferably a pyrrole ring, an imidazole ring, a pyrazole ring, a pyridine ring, a pyrimidine ring, a pyrazoline ring, an indazole ring, A pyridazine ring, a pyrazoline ring, a triazine ring, a pyrazosin ring, a triazole ring, a piperidine ring, a benzimidazole ring.
作為上述取代基列舉之烷基列舉為甲基、乙基、正丙基、異丙基、環丙基,作為上述烷氧基可列舉為作為前述烷基之具體例所列舉之基上鍵結氧原子-O-而成之基。且作為上述含氟烷基、含氟烷氧基可列舉為前述烷基及烷氧基中任意之氫原子以氟原子取代之基。 The alkyl group as the above-mentioned substituent is exemplified by a methyl group, an ethyl group, a n-propyl group, an isopropyl group or a cyclopropyl group, and the above alkoxy group may be exemplified by the above-mentioned alkyl group as a specific example of the above-mentioned alkyl group. The oxygen atom is O-based. Further, the fluorine-containing alkyl group or the fluorine-containing alkoxy group may be a group in which any one of the alkyl group and the alkoxy group is substituted with a fluorine atom.
該等中,就合成容易之觀點而言,Y2較好為苯環或環己烷環。 Among these, Y 2 is preferably a benzene ring or a cyclohexane ring from the viewpoint of easy synthesis.
上述式[1]中,Y3表示單鍵或碳原子數1~15之伸烷基。 In the above formula [1], Y 3 represents a single bond or an alkylene group having 1 to 15 carbon atoms.
上述式[1]中,Y4表示單鍵、或表示由苯環、環己烷環或雜環選出之2價環狀基,該等環狀基上之任意 氫原子亦可以碳原子數1~3之烷基、碳原子數1~3之烷氧基、碳原子數1~3之含氟烷基、碳原子數1~3之含氟烷氧基或氟原子取代。 In the above formula [1], Y 4 represents a single bond or a divalent cyclic group selected from a benzene ring, a cyclohexane ring or a hetero ring, and any hydrogen atom on the ring group may have a carbon number of 1 An alkyl group of ~3, an alkoxy group having 1 to 3 carbon atoms, a fluorine-containing alkyl group having 1 to 3 carbon atoms, a fluorine-containing alkoxy group having 1 to 3 carbon atoms or a fluorine atom.
上述雜環及作為取代基列舉之烷基等可由前述之Y2所列舉者。 The above heterocyclic ring and the alkyl group as a substituent may be exemplified by the above Y 2 .
再者,Y4亦可為由碳原子數17~30之具有類固醇骨架之有機基選出之2價有機基。其較佳之例為具有由選自膽甾醇基(cholesteryl)、雄甾醇基(androsteryl)、β-膽甾醇基、表雄甾醇基(epiandrosteryl)、麥角固醇基(ergosteryl)、雌甾醇基、11α-羥基甲基硬脂基、11α-孕甾素基(progesteryl)、羊毛固醇基(lanosteryl)、麥拉托林基(meratranyl)、甲基睪固醇基(methyltestosteryl)、去甲脫氫羥孕酮基(norethisteryl)、孕烯醇基、β-谷甾醇基(sitosteryl)、豆甾醇基(stigmasteryl)、睪固醇基(testosteryl)、及乙酸膽固醇酯等之構造去除2個氫原子而成之構造之2價基。更具體而言,例如下述。 Further, Y 4 may be a divalent organic group selected from an organic group having a steroid skeleton having 17 to 30 carbon atoms. Preferred examples thereof are those selected from the group consisting of cholesteryl, androsteryl, β-cholesteryl, epiandrosteryl, ergosteryl, and estradiol. 11α-hydroxymethylstearyl, 11α-progesteryl, lanosteryl, meratranyl, methyltestosteryl, desmethyl dehydrogenation The structure of norethisteryl, pregnenol, beta-sterosteryl, stigmasteryl, testosteryl, and cholesteryl acetate removes two hydrogen atoms. The two-valent base of the structure. More specifically, for example, the following.
(式中,*表示鍵結位置)。該等中,就合成容易之觀點而言,Y4較好為苯環、環己烷環或碳原子數17~30之具有類固醇骨架之2價有機基。 (where * indicates the bond position). Among these, Y 4 is preferably a benzene ring, a cyclohexane ring or a divalent organic group having a steroid skeleton having 17 to 30 carbon atoms from the viewpoint of easy synthesis.
式[1]中,Y5表示由苯環、環己烷環或雜環選出之2價環狀基,該環狀基上之任意氫原子亦可以碳原子 數1~3之烷基、碳原子數1~3之烷氧基、碳原子數1~3之含氟烷基、碳原子數1~3之含氟烷氧基或氟原子取代。上述雜環及作為取代基列舉之烷基等可為於前述Y4列舉者。 In the formula [1], Y 5 represents a divalent cyclic group selected from a benzene ring, a cyclohexane ring or a hetero ring, and any hydrogen atom on the cyclic group may be an alkyl group having 1 to 3 carbon atoms or carbon. The alkoxy group having 1 to 3 atomic atoms, the fluorine-containing alkyl group having 1 to 3 carbon atoms, the fluorine-containing alkoxy group having 1 to 3 carbon atoms or a fluorine atom is substituted. The above heterocyclic ring, an alkyl group or the like as a substituent may be listed in the above Y 4 .
該等中,Y5較好為苯環或環己烷環。 Among these, Y 5 is preferably a benzene ring or a cyclohexane ring.
且式[1]中,n表示0~4之整數,n為2以上時,Y5彼此可為相同之基亦可為不同之基。其中,就原料之取得性或合成容易之觀點而言,n較好為0~3。更好為0~2。 In the formula [1], n represents an integer of 0 to 4, and when n is 2 or more, the groups in which Y 5 may be the same may be different groups. Among them, n is preferably from 0 to 3 from the viewpoint of availability of raw materials or ease of synthesis. Better is 0~2.
式[1]中,Y6表示氫原子、碳原子數1~18之烷基、碳原子數1~18之含氟烷基、碳原子數1~18之烷氧基或碳原子數1~18之含氟烷氧基。 In the formula [1], Y 6 represents a hydrogen atom, an alkyl group having 1 to 18 carbon atoms, a fluorine-containing alkyl group having 1 to 18 carbon atoms, an alkoxy group having 1 to 18 carbon atoms or a carbon number of 1~. 18 fluoroalkoxy.
其中,Y6較好為碳原子數1~18之烷基、碳原子數1~10之含氟烷基、碳原子數1~18之烷氧基或碳原子數1~10之含氟烷氧基。更好,Y6為碳原子數1~12之烷基或碳原子數1~12之烷氧基。最好,Y6為碳原子數1~9之烷基或碳原子數1~9之烷氧基。 Among them, Y 6 is preferably an alkyl group having 1 to 18 carbon atoms, a fluorine-containing alkyl group having 1 to 10 carbon atoms, an alkoxy group having 1 to 18 carbon atoms or a fluorine-containing alkane having 1 to 10 carbon atoms. Oxygen. More preferably, Y 6 is an alkyl group having 1 to 12 carbon atoms or an alkoxy group having 1 to 12 carbon atoms. Preferably, Y 6 is an alkyl group having 1 to 9 carbon atoms or an alkoxy group having 1 to 9 carbon atoms.
又,Y4為具有類固醇骨架之2價有機基時,Y6較好為氫原子。 Further, when Y 4 is a divalent organic group having a steroid skeleton, Y 6 is preferably a hydrogen atom.
上述式[1]中之定義中列舉之伸烷基、烷基、含氟烷基、烷氧基或含氟烷氧基可為直鏈狀、分支狀或環狀之任一種或該等之組合。 The alkylene group, the alkyl group, the fluorine-containing alkyl group, the alkoxy group or the fluorine-containing alkoxy group exemplified in the above formula [1] may be any one of a linear chain, a branched chain or a cyclic group or the like. combination.
例如上述烷基列舉為例如甲基、乙基、正丙基、異丙基、正丁基、異丁基、第二丁基、第三丁基、正戊基、1-甲基-正丁基、2-甲基-正丁基、3-甲基-正丁基、1,1-二甲 基-正丙基、1,2-二甲基-正丙基、2,2-二甲基-正丙基、1-乙基-正丙基、正己基、1-甲基-正戊基、2-甲基-正戊基、3-甲基-正戊基、4-甲基-正戊基、1,1-二甲基-正丁基、1,2-二甲基-正丁基、1,3-二甲基-正丁基、2,2-二甲基-正丁基、2,3-二甲基-正丁基、3,3-二甲基-正丁基、1-乙基-正丁基、2-乙基-正丁基、1,1,2-三甲基-正丙基、1,2,2-三甲基-正丙基、1-乙基-1-甲基-正丙基、1-乙基-2-甲基-正丙基、正庚基、1-甲基-正己基、2-甲基-正己基、3-甲基-正己基、1,1-二甲基-正戊基、1,2-二甲基-正戊基、1,3-二甲基-正戊基、2,2-二甲基-正戊基、2,3-二甲基-正戊基、3,3-二甲基-正戊基、1-乙基-正戊基、2-乙基-正戊基、3-乙基-正戊基、1-甲基-1-乙基-正丁基、1-甲基-2-乙基-正丁基、1-乙基-2-甲基-正丁基、2-甲基-2-乙基-正丁基、2-乙基-3-甲基-正丁基、正辛基、1-甲基-正庚基、2-甲基-正庚基、3-甲基-正庚基、1,1-二甲基-正己基、1,2-二甲基-正己基、1,3-二甲基-正己基、2,2-二甲基-正己基、2,3-二甲基-正己基、3,3-二甲基-正己基、1-乙基-正己基、2-乙基-正己基、3-乙基-正己基、1-甲基-1-乙基-正戊基、1-甲基-2-乙基-正戊基、1-甲基-3-乙基-正戊基、2-甲基-2-乙基-正戊基、2-甲基-3-乙基-正戊基、3-甲基-3-乙基-正戊基、正壬基、正癸基、正十一烷基、正十二烷基、正十三烷基、正十四烷基、正十五烷基等。 For example, the above alkyl group is exemplified by, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, t-butyl, n-pentyl, 1-methyl-n-butyl Base, 2-methyl-n-butyl, 3-methyl-n-butyl, 1,1-dimethyl Base-n-propyl, 1,2-dimethyl-n-propyl, 2,2-dimethyl-n-propyl, 1-ethyl-n-propyl, n-hexyl, 1-methyl-n-pentyl , 2-methyl-n-pentyl, 3-methyl-n-pentyl, 4-methyl-n-pentyl, 1,1-dimethyl-n-butyl, 1,2-dimethyl-n-butyl Base, 1,3-dimethyl-n-butyl, 2,2-dimethyl-n-butyl, 2,3-dimethyl-n-butyl, 3,3-dimethyl-n-butyl, 1-ethyl-n-butyl, 2-ethyl-n-butyl, 1,1,2-trimethyl-n-propyl, 1,2,2-trimethyl-n-propyl, 1-ethyl -1-methyl-n-propyl, 1-ethyl-2-methyl-n-propyl, n-heptyl, 1-methyl-n-hexyl, 2-methyl-n-hexyl, 3-methyl-positive 1,1,1-dimethyl-n-pentyl, 1,2-dimethyl-n-pentyl, 1,3-dimethyl-n-pentyl, 2,2-dimethyl-n-pentyl, 2,3-Dimethyl-n-pentyl, 3,3-dimethyl-n-pentyl, 1-ethyl-n-pentyl, 2-ethyl-n-pentyl, 3-ethyl-n-pentyl , 1-methyl-1-ethyl-n-butyl, 1-methyl-2-ethyl-n-butyl, 1-ethyl-2-methyl-n-butyl, 2-methyl-2- Ethyl-n-butyl, 2-ethyl-3-methyl-n-butyl, n-octyl, 1-methyl-n-heptyl, 2-methyl-n-heptyl, 3- Base-n-heptyl, 1,1-dimethyl-n-hexyl, 1,2-dimethyl-n-hexyl, 1,3-dimethyl-n-hexyl, 2,2-dimethyl-n-hexyl, 2,3-Dimethyl-n-hexyl, 3,3-dimethyl-n-hexyl, 1-ethyl-n-hexyl, 2-ethyl-n-hexyl, 3-ethyl-n-hexyl, 1-methyl 1-ethyl-n-pentyl, 1-methyl-2-ethyl-n-pentyl, 1-methyl-3-ethyl-n-pentyl, 2-methyl-2-ethyl-n-pentyl Base, 2-methyl-3-ethyl-n-pentyl, 3-methyl-3-ethyl-n-pentyl, n-decyl, n-decyl, n-undecyl, n-dodecyl, N-tridecyl, n-tetradecyl, n-pentadecyl and the like.
上述伸烷基可列舉為自前述烷基去除1個任意之氫原子而成之二價基。 The alkylene group may be a divalent group obtained by removing one arbitrary hydrogen atom from the alkyl group.
上述烷氧基可列舉為作為前述烷氧基之具體例列舉之基上鍵結氧原子-O-而成之基。 The alkoxy group may be a group in which an oxygen atom -O- is bonded to the group as a specific example of the alkoxy group.
又上述含氟烷基、含氟烷氧基可列前述烷基及烷氧基中任意之氫原子以氟原子取代之基。 Further, the fluorine-containing alkyl group or the fluorine-containing alkoxy group may be a group in which any one of the alkyl group and the alkoxy group is substituted with a fluorine atom.
作為上述Y2及Y3之伸烷基、以及環狀基上之取代基或作為Y6之烷基、含氟烷基、烷氧基及含氟烷氧基可為直鏈狀、分支狀、或環狀之任一種或該等之組合。 The alkylene group of the above Y 2 and Y 3 and the substituent on the cyclic group or the alkyl group as Y 6 , the fluorine-containing alkyl group, the alkoxy group and the fluorine-containing alkoxy group may be linear or branched. Or one of the rings or a combination of these.
又,作為Y2及Y3之伸烷基,以及作為Y6之烷基、含氟烷基、烷氧基及含氟烷氧基只要鍵結基彼此不相鄰則亦可以1至3個鍵結基中斷。 Further, the alkylene group as Y 2 and Y 3 and the alkyl group, fluorine-containing alkyl group, alkoxy group and fluorine-containing alkoxy group as Y 6 may be one to three as long as the bonding groups are not adjacent to each other. The key node is interrupted.
此外,Y2、Y4或Y5表示之2價環狀基,或Y4表示具有類固醇骨架之2價有機基,或Y2或Y3表示伸烷基,或Y6表示烷基或含氟烷基時,該2價環狀基、該具有類固醇骨架之2價有機基、該-CH2-CH(OH)-CH2-、該伸烷基、該烷基及該含氟烷基亦可透過鍵結基與該等所鄰接之基鍵結。 Further, Y 2 , Y 4 or Y 5 represents a divalent cyclic group, or Y 4 represents a divalent organic group having a steroid skeleton, or Y 2 or Y 3 represents an alkylene group, or Y 6 represents an alkyl group or a a fluoroalkyl group, the divalent cyclic group, the divalent organic group having a steroid skeleton, the -CH 2 -CH(OH)-CH 2 -, the alkylene group, the alkyl group and the fluorine-containing alkyl group The bond group may also be bonded to the adjacent base.
且上述鍵結基係表示由-O-、-CH2O-、-CO-、-COO-、-OCO-、-NHCO-、-CONH-、-NH-CO-O-、-O-CO-NH-及-NH-CO-NH-所組成之群選出之基。 And the above bonding group is represented by -O-, -CH 2 O-, -CO-, -COO-, -OCO-, -NHCO-, -CONH-, -NH-CO-O-, -O-CO The group selected from the group consisting of -NH- and -NH-CO-NH-.
又,Y2至Y6分別表示之碳原子數1~15之伸烷基、苯環、環己烷環、雜環、具有類固醇骨架之2價有機基、碳原子數1~18之烷基、碳原子數1~18之含氟烷基、碳原子數1~18之烷氧基及碳原子數1~18之含氟烷氧基之碳原 子數之合計為6~30,例如6~20。 Further, Y 2 to Y 6 each represent an alkylene group having 1 to 15 carbon atoms, a benzene ring, a cyclohexane ring, a heterocyclic ring, a divalent organic group having a steroid skeleton, and an alkyl group having 1 to 18 carbon atoms. The total number of carbon atoms of the fluorine-containing alkyl group having 1 to 18 carbon atoms, the alkoxy group having 1 to 18 carbon atoms, and the fluorine-containing alkoxy group having 1 to 18 carbon atoms is 6 to 30, for example, 6~. 20.
該等中,考慮垂直配向性與聚合性液晶之塗佈性時,垂直配向基以含碳原子數7~18,尤其是8~15之烷基之基較佳。 In the above, in consideration of the applicability of the vertical alignment property and the polymerizable liquid crystal, the vertical alignment group is preferably a group having an alkyl group having 7 to 18 carbon atoms, particularly 8 to 15 carbon atoms.
較好,具有羧基及垂直配向性基之化合物係羧基鍵結於上述垂直配向性基之化合物。 Preferably, the compound having a carboxyl group and a vertical alignment group is a compound in which a carboxyl group is bonded to the above-mentioned vertical alignment group.
本發明中之(A)成分之垂直配向聚合物係具有羧基及垂直配向性基之化合物之羧基對前述側鏈或末端具有1個以上環氧基之聚合物之環氧基進行反應而成之聚合物。藉由該環氧基與羧基反應,而生成如-CH2-CH(OH)-CH2-之鍵結。 In the present invention, the vertical alignment polymer of the component (A) is obtained by reacting a carboxyl group of a compound having a carboxyl group and a vertical alignment group with an epoxy group of a polymer having one or more epoxy groups at the side chain or terminal group. polymer. By the reaction of the epoxy group with a carboxyl group, a bond such as -CH 2 -CH(OH)-CH 2 - is formed.
用以獲得上述垂直配向聚合物之側鏈或末端具有1個以上環氧基之聚合物與具有羧基及垂直配向性基之化合物之使用量,較好以使具有羧基及垂直配向性基之化合物之羧基相對於側鏈或末端具有1個以上環氧基之聚合物之環氧基1當量成為5~60當量之方式使用。 A compound having a carboxyl group and a vertical alignment group, and a compound having a carboxyl group and a vertical alignment group, preferably having a side chain or a terminal group of the above-mentioned vertical alignment polymer, is preferably used to give a compound having a carboxyl group and a vertical alignment group. The carboxyl group is used in an amount of 5 to 60 equivalents per 1 equivalent of the epoxy group of the polymer having one or more epoxy groups in the side chain or the terminal.
相對於側鏈或末端具有1個以上環氧基之聚合物之環氧基1當量,具有羧基及垂直配向性基之化合物之羧基未達5當量時,會有所得垂直配向聚合物中無法充分獲得期望之垂直配向性之情況。且,具有羧基及垂直配向性基之化合物之羧基超過60當量時,使用該垂直配向聚合物形成硬化膜(配向材),且於其上塗佈聚合性液晶溶液等時會有液晶之塗佈性下降(發生液晶不沾著)之虞。 When the epoxy group of the polymer having one or more epoxy groups in the side chain or the terminal is 1 equivalent, and the carboxyl group of the compound having a carboxyl group and a vertical alignment group is less than 5 equivalents, the obtained vertical alignment polymer may not be sufficient. Obtain the desired vertical alignment. Further, when the carboxyl group of the compound having a carboxyl group and a vertical alignment group exceeds 60 equivalents, a cured film (orienting material) is formed using the vertical alignment polymer, and liquid crystal coating is applied when a polymerizable liquid crystal solution or the like is applied thereon. The decline in sex (the liquid crystal does not get stuck).
且,亦可使與具有羧基及垂直配向性基之化合物反應 之於側鏈或末端具有1個以上環氧基之聚合物之環氧殘基與不含垂直配向性基而具有羧基之化合物反應。該情況下,羧基之量相對於側鏈或末端具有1個以上環氧基之聚合物之環氧基1當量,具有羧基及垂直配向性基之化合物之羧基、與不含有垂直配向性基而具有羧基之化合物之羧基之合計量較好為5~60當量。 Also, it is also possible to react with a compound having a carboxyl group and a vertical alignment group. The epoxy residue of the polymer having one or more epoxy groups at the side chain or the terminal is reacted with a compound having a carboxyl group without a vertical alignment group. In this case, the amount of the carboxyl group is 1 equivalent to the epoxy group of the polymer having one or more epoxy groups in the side chain or the terminal, and the carboxyl group of the compound having a carboxyl group and a vertical alignment group does not contain a vertical alignment group. The total amount of the carboxyl groups of the compound having a carboxyl group is preferably from 5 to 60 equivalents.
獲得本發明所用之垂直配向聚合物之順序並無特別限制,例如,使側鏈或末端具有1個以上環氧基之聚合物,與具有羧基及垂直配向性基之化合物,及視情況不含垂直配向性基而具有羧基之化合物在共存有反應觸媒等之溶劑中,於50至150℃之溫度下反應而獲得。此時,所用之溶劑只要是使側鏈或末端具有1個以上環氧基之聚合物與具有羧基及垂直配向性基之化合物、及聚合起起始劑等溶解者即無特別限制。其具體例可使用後述之〈溶劑〉中列舉者。作為反應觸媒列舉為氯化苄基三甲基銨、溴化苄基三甲基銨、氯化苄基三乙基銨、溴化苄基三乙基銨、氯化苄基三丙基銨、溴化苄基三丙基銨、氯化四甲基銨、溴化四乙基銨、氯化四丙基銨、溴化四丙基銨等四級銨鹽;氯化四苯基鏻、溴化四苯基鏻、氯化苄基三苯基鏻、溴化苄基三苯基鏻、氯化乙基三苯基鏻、溴化乙基三苯基鏻等4及鏻鹽等。 The order of obtaining the vertical alignment polymer used in the present invention is not particularly limited, and for example, a polymer having one or more epoxy groups in a side chain or a terminal, a compound having a carboxyl group and a vertical alignment group, and optionally, The compound having a carboxyl group as a vertical alignment group is obtained by reacting at a temperature of 50 to 150 ° C in a solvent in which a reaction catalyst or the like is present. In this case, the solvent to be used is not particularly limited as long as it is a polymer having one or more epoxy groups in a side chain or a terminal, a compound having a carboxyl group and a vertical alignment group, and a polymerization starting agent. Specific examples thereof can be referred to as those described in <Solvents> which will be described later. The reaction catalysts are benzyltrimethylammonium chloride, benzyltrimethylammonium bromide, benzyltriethylammonium chloride, benzyltriethylammonium bromide, benzyltripropylammonium chloride. a quaternary ammonium salt such as benzyltripropylammonium bromide, tetramethylammonium chloride, tetraethylammonium bromide, tetrapropylammonium chloride or tetrapropylammonium bromide; tetraphenylphosphonium chloride; Tetraphenylphosphonium bromide, benzyltriphenylphosphonium chloride, benzyltriphenylphosphonium bromide, ethyltriphenylphosphonium chloride, ethyltriphenylphosphonium bromide, and the like, and an onium salt.
以前述方法獲得之垂直配向聚合物通常為溶解於溶劑中之溶液狀態。如後述,所得垂直配向聚合物之溶液可直接作為(A)成分(之溶液)使用。 The vertically aligned polymer obtained by the aforementioned method is usually in the form of a solution dissolved in a solvent. As will be described later, the solution of the obtained vertically-oriented polymer can be directly used as the (component) (A) solution.
且,將以上述方法所得之垂直配向聚合物之溶液投入攪拌下之二乙基醚或水等中再沉澱,使生成之沉澱物過濾‧洗淨後,在常壓或減壓下,經常溫乾燥或加熱乾燥,可成為垂直配向聚合物之粉體。藉由前述操作,可去除與垂直配向聚合物共存之反應觸媒及未反應觸媒,結果,獲得經純化之垂直配向聚合物之粉體。在一次操作未充分純化時,只要將所得粉體再溶解於溶劑中,重複進行上述操作即可。 Further, the solution of the vertically aligned polymer obtained by the above method is poured into diethyl ether or water under stirring to reprecipitate, and the resulting precipitate is filtered. After washing, it is heated at normal pressure or reduced pressure. Drying or heating and drying can be a powder of a vertically aligned polymer. By the foregoing operation, the reaction catalyst and the unreacted catalyst coexisting with the vertically aligned polymer can be removed, and as a result, the powder of the purified vertically aligned polymer can be obtained. When the primary operation is not sufficiently purified, the obtained powder may be redissolved in a solvent, and the above operation may be repeated.
本發明中,垂直配向聚合物可以粉體形態使用,或者亦可將經純化之粉末再溶解於後述溶劑中而成之溶液形態使用。 In the present invention, the vertical alignment polymer may be used in the form of a powder, or may be used in the form of a solution obtained by redissolving the purified powder in a solvent to be described later.
又,本發明中,(A)成分之垂直配向聚合物亦可為複數種之垂直配向聚合物之混合物。 Further, in the present invention, the vertically-aligned polymer of the component (A) may also be a mixture of a plurality of vertically-aligned polymers.
本發明之硬化膜形成組成物中之(B)成分為交聯劑。 The component (B) in the cured film forming composition of the present invention is a crosslinking agent.
(B)成分之交聯劑較好為具有可與前述(A)成分之可熱交聯官能基形成交聯之基,例如具有羥甲基或烷氧基甲基之交聯劑。具有該等基之化合物列舉為例如烷氧基甲基化甘醇脲、烷氧基甲基化苯胍及烷氧基甲基化三聚氰胺等羥甲基化合物。 The crosslinking agent of the component (B) is preferably a group having a crosslinking group which can form a crosslinking with the thermally crosslinkable functional group of the above component (A), for example, a crosslinking agent having a methylol group or an alkoxymethyl group. The compound having such a group is exemplified by a methylol compound such as an alkoxymethylated glycol urea, an alkoxymethylated benzoquinone or an alkoxymethylated melamine.
烷氧基甲基化甘醇脲之具體例列舉為例如1,3,4,6-肆(甲氧基甲基)甘醇脲、1,3,4,6-肆(丁氧基甲 基)甘醇脲、1,3,4,6-肆(羥基甲基)甘醇脲、1,3-雙(羥基甲基)尿素、1,1,3,3-肆(丁氧基甲基)尿素、1,1,3,3-肆(甲氧基甲基)尿素、1,3-雙(羥基甲基)-4,5-二羥基-2-咪唑酮、及1,3-雙(甲氧基甲基)-4,5-二甲氧基-2-咪唑酮等。市售品列舉為日本Scientech Industries(股)(舊三井Scientech(股))製之甘醇脲化合物(商品名:CYMEL(註冊商標)1170,Powder Link(註冊商標)1174)等之化合物,甲基化尿素樹脂(商品名:UFR(註冊商標)65)、甲基化尿素樹脂(商品名:UFR(註冊商標)300、U-VAN10S60、U-VAN10R、U-VAN11HV)、DIC(股)(舊大日本油墨化學工業(股))製之尿素/甲醛系樹脂(高縮合型,商品名:BECKAMINE(註冊商標)J-300S、BECKAMINE P-955、BECKAMINE N)等。 Specific examples of the alkoxymethylated glycol urea are, for example, 1,3,4,6-fluorene (methoxymethyl)glycol urea, 1,3,4,6-fluorene (butoxyl) Glycol urea, 1,3,4,6-indole (hydroxymethyl) glycol urea, 1,3-bis(hydroxymethyl) urea, 1,1,3,3-indole (butoxymethyl) Base, urea, 1,1,3,3-indole (methoxymethyl) urea, 1,3-bis(hydroxymethyl)-4,5-dihydroxy-2-imidazolidone, and 1,3- Bis(methoxymethyl)-4,5-dimethoxy-2-imidazolidone and the like. The commercially available product is a compound such as a glycol urea compound (trade name: CYMEL (registered trademark) 1170, Powder Link (registered trademark) 1174) manufactured by Scientech Industries Co., Ltd., Japan. Urea resin (trade name: UFR (registered trademark) 65), methylated urea resin (trade name: UFR (registered trademark) 300, U-VAN10S60, U-VAN10R, U-VAN11HV), DIC (share) (old Urea/formaldehyde resin (high condensation type, trade name: BECKAMINE (registered trademark) J-300S, BECKAMINE P-955, BECKAMINE N) manufactured by Dainippon Ink Chemical Industry Co., Ltd.).
烷氧基甲基化苯胍之具體例例舉為四甲氧基甲基苯胍等。市售品列舉為日本Scientech Industries(股)(舊三井Scientech(股))製(商品名:CYMEL(註冊商標)1123)、三和化學(股)製(商品名:NIKALAC(註冊商標)BX-4000、NIKALAC BX-37、NIKALAC BL-60、NIKALAC BX-55H)等。 Specific examples of the alkoxymethylated benzoquinone include tetramethoxymethylphenylhydrazine and the like. Commercially available products are manufactured by Japan Scientech Industries Co., Ltd. (trade name: CYMEL (registered trademark) 1123) and Sanwa Chemical Co., Ltd. (trade name: NIKALAC (registered trademark) BX- 4000, NIKALAC BX-37, NIKALAC BL-60, NIKALAC BX-55H), etc.
烷氧基甲基化三聚氰胺之具體例列舉為例如六甲氧基甲基三聚氰胺。市售品列舉為例如日本Scientech Industries(股)(舊三井Scientech(股))製之甲氧基甲基型三聚氰胺化合物(商品名:CYMEL(註冊商標)300、CYMEL 301、CYMEL 303、CYMEL 350)、丁氧基甲基型三聚氰胺化合物(商品名:MYCOTE(註冊商標)506、MYCOTE 508)、三和化學(股)製之甲氧甲基型三聚氰胺化合物(商品名:NIKALAC(註冊商標)MW-30、NIKALAC MW-22、NIKALAC MW-11、NIKALAC MS-001、NIKALAC MX-002、NIKALAC MX-730、NIKALAC MX-750、NIKALAC MX-035)、丁氧基甲基型三聚氰胺化合物(商品名:NIKALAC(註冊商標)MX-45、NIKALAC MX-410、NIKALAC MX-302)等。 Specific examples of the alkoxymethylated melamine are, for example, hexamethoxymethylmelamine. Commercially available products are, for example, methoxymethyl type melamine compounds manufactured by Scientech Industries, Ltd. (trade name: CYMEL (registered trademark) 300, CYMEL 301, CYMEL 303, CYMEL, manufactured by Scientech Industries, Japan. 350), a methoxymethyl type melamine compound (trade name: MYCOTE (registered trademark) 506, MYCOTE 508), a methoxymethyl type melamine compound manufactured by Sanwa Chemical Co., Ltd. (trade name: NIKALAC (registered trademark) MW-30, NIKALAC MW-22, NIKALAC MW-11, NIKALAC MS-001, NIKALAC MX-002, NIKALAC MX-730, NIKALAC MX-750, NIKALAC MX-035), butoxymethyl melamine compound (commodity) Name: NIKALAC (registered trademark) MX-45, NIKALAC MX-410, NIKALAC MX-302).
且,亦可為使此等胺基之氫原子以羥甲基或烷氧基甲基取代之三聚氰胺化合物、尿素化合物、甘醇脲化合物及苯胍化合物縮合而得之化合物。列舉為例如,美國專利第6323310號中記載之三聚氰胺化合物及由苯胍化合物製造之高分子量化合物。前述三聚氰胺化合物之市售品列舉為商品名:CYMEL(註冊商標)303等,前述苯胍化合物之市售品列舉為商品名CYMEL(註冊商標)1123(以上為日本Scientech Industries(股)製)等。 Further, it may be a compound obtained by condensing a melamine compound, a urea compound, a glycol urea compound, and a benzoquinone compound in which a hydrogen atom of these amine groups is substituted with a methylol group or an alkoxymethyl group. For example, a melamine compound described in U.S. Patent No. 6,323,310 and a high molecular weight compound produced from a benzoquinone compound are listed. The commercially available product of the melamine compound is CYMEL (registered trademark) 303, and the like, and the commercial product of the benzoquinone compound is CYMEL (registered trademark) 1123 (the above is manufactured by Scientech Industries, Japan). .
再者,(B)成分之交聯劑亦可利用使用N-羥基甲基丙烯醯胺、N-甲氧基甲基甲基丙烯醯胺、N-乙氧基甲基丙烯醯胺、N-丁氧基甲基甲基丙烯醯胺等之以羥基甲基(亦即羥甲基)或烷氧基甲基取代之丙烯醯胺化合物或甲基丙烯醯胺化合物所製造之聚合物。 Further, the crosslinking agent of the component (B) may also be used by using N-hydroxymethyl acrylamide, N-methoxymethyl methacrylamide, N-ethoxymethyl acrylamide, N- A polymer produced by a acrylamide compound or a methacrylamide compound substituted with a hydroxymethyl group (i.e., a methylol group) or an alkoxymethyl group, such as butoxymethylmethacrylamide.
作為此種聚合物列舉為例如聚(N-丁氧基甲基丙烯醯胺)、N-丁氧基甲基丙烯醯胺與苯乙烯之共聚 物、N-羥基甲基甲基丙烯醯胺與甲基丙烯酸甲酯之共聚物、N-乙氧基甲基甲基丙烯醯胺與甲基丙烯酸苄酯之共聚物、及N-丁氧基甲基丙烯醯胺與甲基丙烯酸苄酯與甲基丙烯酸2-羥基丙酯之共聚物等。該等聚合物之重量平均分子量(聚苯乙烯換算值)為1,000~500,000,較好為2,000~200,000,更好為3,000~150,000,又更好為3,000~50,000。 As such a polymer, for example, copolymerization of poly(N-butoxymethyl acrylamide), N-butoxymethyl acrylamide and styrene is exemplified. a copolymer of N-hydroxymethylmethacrylamide and methyl methacrylate, a copolymer of N-ethoxymethylmethacrylamide and benzyl methacrylate, and N-butoxy a copolymer of methacrylamide and benzyl methacrylate with 2-hydroxypropyl methacrylate. The weight average molecular weight (polystyrene conversion value) of the polymers is from 1,000 to 500,000, preferably from 2,000 to 200,000, more preferably from 3,000 to 150,000, still more preferably from 3,000 to 50,000.
該等交聯劑可單獨使用或組合2種以上使用。 These crosslinking agents may be used singly or in combination of two or more.
本發明之硬化膜形成組成物中之(B)成分之交聯劑含量,基於(A)成分的化合物100質量份,較好為1質量份~100質量份,更好為5質量份~80質量份。交聯劑之含量過小時,由硬化膜形成組成物所得之硬化膜之耐溶劑性降低,且垂直配向性降低。另一方面,含量過大時會有垂直配向性及保存安定性降低之情況。 The content of the crosslinking agent of the component (B) in the cured film formation composition of the present invention is preferably from 1 part by mass to 100 parts by mass, more preferably from 5 parts by mass to 80 parts by mass based on 100 parts by mass of the compound of the component (A). Parts by mass. When the content of the crosslinking agent is too small, the solvent resistance of the cured film obtained by forming the composition from the cured film is lowered, and the vertical alignment property is lowered. On the other hand, when the content is too large, there is a case where the vertical alignment property and the storage stability are lowered.
本發明之硬化膜形成組成物中之(C)成分為酸觸媒。 The component (C) in the cured film forming composition of the present invention is an acid catalyst.
(C)成分的酸觸媒可適當地使用例如酸或熱酸產生劑。該(C)成分對於促進本發明之硬化膜形成組成物之熱硬化反應有效。 As the acid catalyst of the component (C), for example, an acid or a thermal acid generator can be suitably used. The component (C) is effective for promoting the thermosetting reaction of the cured film forming composition of the present invention.
(C)成分具體列舉為作為上述酸之含磺酸基之化合物、鹽酸或其鹽。而且上述熱酸產生劑只要是加熱處理時 經熱分解而產生酸之化合物,亦即在溫度80℃至250℃會熱分解而產生酸之化合物即可,並無特別限制。 The component (C) is specifically exemplified by a sulfonic acid group-containing compound as the above acid, hydrochloric acid or a salt thereof. Moreover, the above thermal acid generator is only required to be heat treated The compound which generates an acid by thermal decomposition, that is, a compound which thermally decomposes at a temperature of 80 ° C to 250 ° C to generate an acid, is not particularly limited.
上述酸之具體例列舉為例如鹽酸或其鹽;甲烷磺酸、乙烷磺酸、丙烷磺酸、丁烷磺酸、戊烷磺酸、辛烷磺酸、苯磺酸、對-甲苯磺酸、樟腦磺酸、三氟甲烷磺酸、對-苯酚磺酸、2-萘磺酸、均三甲苯磺酸、對-二甲苯-2-磺酸、間-二甲苯-2-磺酸、4-乙基苯磺酸、1H,1H,2H,2H-全氟辛烷磺酸、全氟(2-乙氧基乙烷)磺酸、五氟乙烷磺酸、九氟丁烷-1-磺酸、十二烷基苯磺酸等之含磺酸基之化合物或其水和物或鹽等。 Specific examples of the above acid are exemplified by hydrochloric acid or a salt thereof; methanesulfonic acid, ethanesulfonic acid, propanesulfonic acid, butanesulfonic acid, pentanesulfonic acid, octanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid , camphorsulfonic acid, trifluoromethanesulfonic acid, p-phenolsulfonic acid, 2-naphthalenesulfonic acid, mesitylenesulfonic acid, p-xylene-2-sulfonic acid, m-xylene-2-sulfonic acid, 4 -ethylbenzenesulfonic acid, 1H, 1H, 2H, 2H-perfluorooctanesulfonic acid, perfluoro(2-ethoxyethane)sulfonic acid, pentafluoroethanesulfonic acid, nonafluorobutane-1- A sulfonic acid group-containing compound such as a sulfonic acid or dodecylbenzenesulfonic acid or a water or a salt thereof.
且藉熱產生酸之化合物列舉為例如雙(甲苯磺醯氧基)乙烷、雙(甲苯磺醯氧基)丙烷、雙(甲苯磺醯氧基)丁烷、對-硝基苄基甲苯磺酸酯、鄰-硝基苄基甲苯磺酸酯、1,2,3-伸苯基參(甲基磺酸酯)、對-甲苯磺酸吡啶鎓鹽、對-甲苯磺酸嗎啉鎓鹽、對-甲苯磺酸乙酯、對-甲苯磺酸丙酯、對-甲苯磺酸丁酯、對-甲苯磺酸異丁酯、對-甲苯磺酸甲酯、對-甲苯磺酸苯乙酯、對-甲苯磺酸氰基甲酯、對-甲苯磺酸2,2,2-三氟乙酯、對-甲苯磺酸2-羥基丁酯、N-乙基-對-甲苯磺醯胺、以及以下述式表示之化合物等:
本發明之硬化膜形成組成物中之(C)成分之含量,相對於(A)成分之化合物100質量份,較好為0.01質量份~20質量份,更好為0.1質量份~15質量份,又更好為0.5質量份~10質量份。藉由將(C)成分之含量設為0.01質量份以上,可賦予充分之熱硬化性及耐溶 劑性。然而,多於20質量份時,會有組成物之保存安定性下降之情況。 The content of the component (C) in the cured film formation composition of the present invention is preferably from 0.01 part by mass to 20 parts by mass, more preferably from 0.1 part by mass to 15 parts by mass, per 100 parts by mass of the compound of the component (A). It is more preferably 0.5 parts by mass to 10 parts by mass. By setting the content of the component (C) to 0.01 parts by mass or more, sufficient thermosetting property and resistance to dissolution can be imparted. Dosage. However, when it is more than 20 parts by mass, the storage stability of the composition may be lowered.
本發明之硬化膜形成組成物主要以溶解於溶劑中之溶液狀態使用。此時使用之溶劑只要可使(A)成分、(B)成分及/或(C)成分、以及可視需要添加之後述其他添加劑溶解即可,其種類及構造等並無特別限制。 The cured film forming composition of the present invention is mainly used in the form of a solution dissolved in a solvent. The solvent to be used at this time is not particularly limited as long as it can dissolve the component (A), the component (B), and/or the component (C), and other additives described later, as needed, and the type and structure thereof.
溶劑之具體例列舉為例如甲醇、乙醇、正丙醇、異丙醇、正丁醇、異丁醇、2-甲基-1-丁醇、正戊醇、乙二醇單甲基醚、乙二醇單乙基醚、甲基溶纖素乙酸酯、乙基溶纖素乙酸酯、二乙二醇、二乙二醇單甲基醚、二乙二醇單乙基醚、丙二醇、丙二醇單甲基醚、丙二醇單甲基醚乙酸酯、丙二醇單乙基醚、丙二醇丙基醚、丙二醇丙基醚乙酸酯、甲苯、二甲苯、甲基乙基酮、異丁基甲基酮、環戊酮、環己酮、2-丁酮、3-甲基-2-戊酮、2-戊酮、2-庚酮、γ-丁內酯、2-羥基丙酸乙酯、2-羥基-2-甲基丙酸乙酯、乙氧基乙酸乙酯、羥基乙酸乙酯、2-羥基-3-甲基丁酸甲酯、3-甲氧基丙酸甲酯、3-甲氧基丙酸乙酯、3-乙氧基丙酸甲酯、3-乙氧基丙酸乙酯、丙酮酸甲酯、丙酮酸乙酯、乙酸乙酯、乙酸丁酯、乳酸乙酯、乳酸丁酯、環戊基甲基醚、N,N-二甲基甲醯胺、N,N-二甲基乙醯胺、及N-甲基-2-吡咯啶酮等。 Specific examples of the solvent are, for example, methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, 2-methyl-1-butanol, n-pentanol, ethylene glycol monomethyl ether, and B. Glycol monoethyl ether, methyl cellosolve acetate, ethyl cellosolve acetate, diethylene glycol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, propylene glycol, Propylene glycol monomethyl ether, propylene glycol monomethyl ether acetate, propylene glycol monoethyl ether, propylene glycol propyl ether, propylene glycol propyl ether acetate, toluene, xylene, methyl ethyl ketone, isobutyl methyl ketone, Cyclopentanone, cyclohexanone, 2-butanone, 3-methyl-2-pentanone, 2-pentanone, 2-heptanone, γ-butyrolactone, ethyl 2-hydroxypropionate, 2-hydroxyl Ethyl 2-methylpropionate, ethyl ethoxyacetate, ethyl hydroxyacetate, methyl 2-hydroxy-3-methylbutanoate, methyl 3-methoxypropionate, 3-methoxy Ethyl propionate, methyl 3-ethoxypropionate, ethyl 3-ethoxypropionate, methyl pyruvate, ethyl pyruvate, ethyl acetate, butyl acetate, ethyl lactate, butyl lactate , cyclopentyl methyl ether, N,N-dimethylformamide, N,N-dimethylacetamide And N- methyl-2-pyrrolidone, and the like.
使用本發明之硬化膜形成組成物,於樹脂膜 上形成硬化膜製造配向材時,甲醇、乙醇、正丙醇、異丙醇、正丁醇、2-甲基-1-丁醇、2-戊醇、異丁基甲基酮、二乙二醇、丙二醇、丙二醇單甲基醚、丙二醇單甲基醚乙酸酯等,就係樹脂膜顯示耐性之溶液之方面係較佳。 Forming a composition using the cured film of the present invention, in a resin film When a cured film is formed thereon to produce a alignment material, methanol, ethanol, n-propanol, isopropanol, n-butanol, 2-methyl-1-butanol, 2-pentanol, isobutyl methyl ketone, diethylene glycol, Propylene glycol, propylene glycol monomethyl ether, propylene glycol monomethyl ether acetate, and the like are preferred in terms of a solution in which the resin film exhibits resistance.
該等溶劑可單獨使用1種或以2種以上組合使用。 These solvents may be used alone or in combination of two or more.
另外,本發明之硬化膜形成組成物只要不損及本發明之效果,則可視需要含有密著提升劑、矽烷偶合劑、界面活性劑、流變調整劑、顏料、染料、保存安定劑、消泡劑、抗氧化劑等。 Further, the cured film forming composition of the present invention may contain a coating enhancer, a decane coupling agent, a surfactant, a rheology modifier, a pigment, a dye, a storage stabilizer, and the like as long as the effect of the present invention is not impaired. Foaming agents, antioxidants, etc.
本發明之硬化膜形成組成物係含有(A)成分之垂直配向聚合物、(B)成分之交聯劑及/或(C)成分之酸觸媒,且視需要只要在不損及本發明效果之範圍內亦可進而含有其他添加劑之組成物。因此通常係以使該等溶解於溶劑中之溶液形態使用。 The cured film forming composition of the present invention contains the vertical alignment polymer of the component (A), the crosslinking agent of the component (B), and/or the acid catalyst of the component (C), and if necessary, does not impair the present invention. Within the scope of the effect, it may further comprise a composition of other additives. Therefore, it is usually used in the form of a solution which dissolves the solvent in a solvent.
本發明之硬化膜形成組成物之較佳例係如下。 Preferred examples of the cured film forming composition of the present invention are as follows.
[1]:基於(A)成分100質量份,含有1質量份~100質量份之(B)成分之硬化膜形成組成物。 [1]: A cured film forming composition containing 1 part by mass to 100 parts by mass of the component (B) based on 100 parts by mass of the component (A).
[2]:基於(A)成分100質量份,含有1質量份~100 質量份之(B)成分、溶劑之硬化膜形成組成物。 [2]: based on 100 parts by mass of the (A) component, containing 1 part by mass to 100% The cured film of the component (B) and the solvent are formed into a composition.
[3]:基於(A)成分100質量份,含有0.01質量份~20質量份之(C)成分、溶劑之硬化膜形成組成物。 [3]: A cured film formation composition containing 0.01 parts by mass to 20 parts by mass of the component (C) and a solvent, based on 100 parts by mass of the component (A).
[4]:基於(A)成分100質量份,含有1質量份~100質量份之(B)成分、0.01質量份~20質量份之(C)成分、溶劑之硬化膜形成組成物。 [4]: A cured film formation composition containing 1 part by mass to 100 parts by mass of the component (B), 0.01 parts by mass to 20 parts by mass of the component (C), and a solvent, based on 100 parts by mass of the component (A).
本發明之硬化膜形成組成物作為溶液使用時之調配比例、調製方法等詳述於下。 The formulation ratio, the preparation method, and the like in the case where the cured film forming composition of the present invention is used as a solution will be described in detail below.
本發明之硬化膜形成組成物中之固體成分之比例只要使各成分均勻地溶解於容劑中即無特別限制,但為1質量%~60質量%,較好為2質量%~50質量%,更好為2質量%~20質量%。此處,所謂固體成分係指自硬化膜形成組成物之全部成分去除溶劑者。 The ratio of the solid content in the cured film formation composition of the present invention is not particularly limited as long as the components are uniformly dissolved in the monomer, but it is 1% by mass to 60% by mass, preferably 2% by mass to 50% by mass. More preferably, it is 2% by mass to 20% by mass. Here, the solid content means a solvent from which all components of the cured film forming composition are removed.
本發明之硬化膜形成組成物之調製方法並無特別限制。調製法列舉為例如於溶解於溶劑中之(A)成分的溶液中,以特定之比例混合(B)成分及/或(C)成分等成為均勻溶液之方法,或者,在其調製法之適當階段,視需要進一步添加其他添加劑並混合之方法。 The method for preparing the cured film forming composition of the present invention is not particularly limited. The preparation method is, for example, a method in which a component (B) and/or a component (C) are mixed in a solution of the component (A) dissolved in a solvent, or a suitable solution is prepared. In the stage, further add other additives and mix as needed.
本發明之硬化膜形成組成物之調製中,可直接使用藉溶劑中之反應所得之垂直配向聚合物之溶液。該情況時,例如與前述同樣將(B)成分及/或(C)成分等饋入(A)成分之溶液中成為均勻溶液。此時,基於調整濃度目的亦可追加投入額外之溶劑。此時,(A)成分之生成過程中所用之溶劑可與硬化膜形成組成物之濃度調 整所用之溶劑相同,亦可不同。 In the preparation of the cured film forming composition of the present invention, a solution of a vertically aligned polymer obtained by a reaction in a solvent can be used as it is. In this case, for example, the component (B) and/or the component (C) are fed into the solution of the component (A) in the same manner as described above to form a homogeneous solution. At this time, an additional solvent may be additionally added for the purpose of adjusting the concentration. At this time, the solvent used in the formation of the component (A) can be adjusted with the concentration of the cured film forming composition. The solvent used is the same or different.
此外,所調製之硬化膜形成組成物之溶液較好使用孔徑0.2μm左右之過濾器等過濾後使用。 Further, the solution of the cured film forming composition to be prepared is preferably filtered using a filter having a pore diameter of about 0.2 μm or the like.
以棒塗佈器、旋轉塗佈、流動塗佈、輥塗佈、狹縫塗佈、狹縫後接續旋轉塗佈、噴墨塗佈、印刷等將本發明之硬化膜形成組成物之溶液塗佈於基板(例如,矽/二氧化矽被覆基板、氮化矽基板、以金屬例如鋁、鉬、鉻等被覆之基板、玻璃基板、石英基板、ITO基板等)或薄膜基板(例如三乙醯基纖維素(TAC)膜、環烯烴聚合物(COP)膜、環烯烴共聚物(COC)膜、聚對苯二甲酸乙二酯(PET)膜、丙烯酸膜、聚乙烯膜等樹脂膜)等上而形成塗膜,隨後,以加熱板或烘箱等加熱乾燥,藉此可形成硬化膜。該硬化膜亦可直接作為配向材使用。 Applying a solution of the cured film of the present invention to a composition by a bar coater, spin coating, flow coating, roll coating, slit coating, slit-spinning spin coating, inkjet coating, printing, or the like A substrate (for example, a tantalum/cerium oxide-coated substrate, a tantalum nitride substrate, a substrate coated with a metal such as aluminum, molybdenum, or chromium, a glass substrate, a quartz substrate, an ITO substrate, or the like) or a thin film substrate (for example, triacetonitrile) Cellulose (TAC) film, cycloolefin polymer (COP) film, cycloolefin copolymer (COC) film, polyethylene terephthalate (PET) film, acrylic film, polyethylene film, etc.) A coating film is formed thereon, and then dried by heating with a hot plate or an oven, whereby a cured film can be formed. The cured film can also be used directly as an alignment material.
加熱乾燥之條件只要不使硬化膜(配向材)之成分溶出於塗佈於其上之聚合性液晶溶液中之程度,而藉交聯劑進行交聯反應即可,例如,採用自溫度60℃~200℃、時間0.4分鐘~60分鐘之範圍中適當選擇之加熱溫度及加熱時間。加熱溫度及加熱時間較好為70℃~160℃,0.5分鐘~10分鐘。 The conditions of heat drying may be carried out by crosslinking the crosslinking agent by a crosslinking agent as long as the components of the cured film (alignment material) are not dissolved in the polymerizable liquid crystal solution applied thereto, for example, at a temperature of 60 ° C. Appropriately selected heating temperature and heating time in the range of ~200 ° C, time 0.4 minutes to 60 minutes. The heating temperature and heating time are preferably from 70 ° C to 160 ° C, from 0.5 minutes to 10 minutes.
使用本發明之硬化性組成物形成之硬化膜(配向材)之膜厚為例如0.05μm~5μm,可考慮所使用之基板之階差或光學、電性性質而適當選擇。 The film thickness of the cured film (orienting material) formed using the curable composition of the present invention is, for example, 0.05 μm to 5 μm, and can be appropriately selected in consideration of the step difference or optical and electrical properties of the substrate to be used.
由本發明之硬化膜組成物形成之配向材由於具有耐溶劑性及耐熱性,故可將具有垂直配向性之聚合性液晶溶液等之相位差材料塗佈於該配向材上,在配向材上配向。而且,藉由照射300~400nm之紫外線使成為配向狀態之相位差材料硬化,可作為具有光學異向性之層形成相位差材。而且,形成配向材之基板為薄膜時,可使用作為相位差薄膜。 Since the alignment material formed of the cured film composition of the present invention has solvent resistance and heat resistance, a phase difference material such as a polymerizable liquid crystal solution having a vertical alignment property can be applied onto the alignment material, and aligned on the alignment material. . Further, the phase difference material which is in the alignment state is cured by irradiation of ultraviolet rays of 300 to 400 nm, and a phase difference material can be formed as a layer having optical anisotropy. Further, when the substrate on which the alignment material is formed is a film, a retardation film can be used.
此外,使用如上述形成之具有本發明之配向材之2片基板,透過間隔件使兩基板上之配向材彼此對向貼合後,將液晶注入於該等基板之間,亦可成為使液晶配向之液晶顯示元件。 Further, by using the two substrates having the alignment material of the present invention formed as described above, the alignment materials on the two substrates are bonded to each other through the spacer, and then liquid crystal is injected between the substrates to form a liquid crystal. Aligned liquid crystal display elements.
如此本發明之硬化膜形成組成物可較好地使用於各種相位差材(相位差薄膜)或液晶顯示元件等之製造中。 The cured film forming composition of the present invention can be preferably used in the production of various phase difference materials (phase difference films) or liquid crystal display elements.
以下舉例更詳細說明本發明,但本發明並不限於該等實施例。 The invention is illustrated in more detail in the following examples, but the invention is not limited to the examples.
以下實施例中使用之簡寫符號意義如下。 The abbreviated symbols used in the following embodiments have the following meanings.
jER-1001:三菱化學(股)製之雙酚A型環氧樹脂 分子量900 jER-1001: bisphenol A epoxy resin manufactured by Mitsubishi Chemical Co., Ltd. Molecular weight 900
jER-1055:三菱化學(股)製之雙酚A型環氧樹脂 分子量1,600 jER-1055: bisphenol A epoxy resin manufactured by Mitsubishi Chemical Co., Ltd. Molecular weight 1,600
jER-157S70:三菱化學(股)製之環氧化雙酚A酚醛清漆樹脂 jER-157S70: epoxidized bisphenol A novolac resin made by Mitsubishi Chemical Corporation
ECN-1299:旭化成(股)製之甲酚酚醛清漆樹脂 ECN-1299: cresol novolac resin made by Asahi Kasei Co., Ltd.
EHPE-3150:Daicel(股)製之三羥甲基丙烷之1,2-環氧基-4-(2-環氧乙基)環己烷加成物 EHPE-3150: 1,2-epoxy-4-(2-epoxyethyl)cyclohexane adduct of trimethylolpropane manufactured by Daicel Co., Ltd.
LAUA:月桂酸 LAUA: Lauric acid
5CCA:4’-戊基-(1,1’-雙環己烷)-4-羧酸 5CCA: 4'-pentyl-(1,1'-bicyclohexane)-4-carboxylic acid
BMAA:N-丁氧基甲基丙烯醯胺 BMAA: N-butoxymethyl acrylamide
BTEAC:氯化苄基三乙基銨 BTEAC: benzyltriethylammonium chloride
AIBN:α,α’-偶氮雙異丁腈 AIBN: α,α'-azobisisobutyronitrile
CYM303:六甲氧基甲基三聚氰胺 CYM303: hexamethoxymethyl melamine
PTSA:對-甲苯磺酸‧單水合物 PTSA: p-toluenesulfonic acid ‧ monohydrate
PM:丙二醇單甲基醚 PM: propylene glycol monomethyl ether
MIBK:異丁基甲基酮 MIBK: isobutyl methyl ketone
根據以下之合成例獲得之丙烯酸共聚物之數 平均分子量及重量平均分子量係使用日本分光(股)製之 GPC裝置(Shodex(註冊商標)管柱KF803L及KF804L),以流量1mL/分鐘使溶出溶劑四氫呋喃流至管柱(管柱溫度40℃)中進行溶離之條件測定。又,下述之數平均分子量(以下稱為Mn)及重量平均分子量(以下稱為Mw)係以聚苯乙烯換算值表示。 The number of acrylic copolymers obtained according to the following synthesis examples The average molecular weight and the weight average molecular weight are made using Japan Spectrophotometer The GPC apparatus (Shodex (registered trademark) column KF803L and KF804L) was measured by flowing the elution solvent tetrahydrofuran to a column (column temperature: 40 ° C) at a flow rate of 1 mL/min. In addition, the following average molecular weight (hereinafter referred to as Mn) and weight average molecular weight (hereinafter referred to as Mw) are expressed in terms of polystyrene.
使jER-1001 50.0g、LAUA 6.25g、BTEAC 0.14g溶解於PM 131.58g中,在110℃反應16小時,藉此獲得垂直配向聚合物(固體成分濃度30質量%)(P1)。測定所得垂直配向聚合物之環氧價,確認使LAUA完全反應之部分的環氧基消失。 JER-1001 50.0 g, LAUA 6.25 g, and BTEAC 0.14 g were dissolved in PM 131.58 g, and reacted at 110 ° C for 16 hours, thereby obtaining a vertical alignment polymer (solid content concentration: 30% by mass) (P1). The epoxy valence of the obtained vertically aligned polymer was measured, and it was confirmed that the epoxy group which partially reacts LAUA disappeared.
使jER-1055 50.0g、LAUA 3.54g、BTEAC 0.079g溶解於PM 125.0g中,在110℃反應16小時,藉此獲得垂直配向聚合物(固體成分濃度30質量%)(P2)。測定所得垂直配向聚合物之環氧價,確認使LAUA完全反應之部分的環氧基消失。 JER-1055 50.0 g, LAUA 3.54 g, and BTEAC 0.079 g were dissolved in PM 125.0 g, and reacted at 110 ° C for 16 hours, thereby obtaining a vertical alignment polymer (solid content concentration: 30% by mass) (P2). The epoxy valence of the obtained vertically aligned polymer was measured, and it was confirmed that the epoxy group which partially reacts LAUA disappeared.
使jER-157S70 50.0g、LAUA 14.3g、BTEAC 0.33g溶解於PM 150.8g中,在110℃反應16小時,藉此獲得垂直配向聚合物(固體成分濃度30質量%)(P3)。測定所 得垂直配向聚合物之環氧價,確認使LAUA完全反應之部分的環氧基消失。 50.0 g of jER-157S70, 14.3 g of LAUA, and 0.33 g of BTEAC were dissolved in 150.8 g of PM, and reacted at 110 ° C for 16 hours to obtain a vertical alignment polymer (solid content concentration: 30% by mass) (P3). Measuring institute The epoxy valence of the vertically aligned polymer was confirmed, and it was confirmed that the epoxy group which partially reacts LAUA disappeared.
使ECN-1299 50.0g、LAUA 14.0g、BTEAC 0.32g溶解於PM 150.2g中,在110℃反應16小時,藉此獲得垂直配向聚合物(固體成分濃度30質量%)(P4)。測定所得垂直配向聚合物之環氧價,確認使LAUA完全反應之部分的環氧基消失。 50.0 g of ECN-1299, 14.0 g of LAUA, and 0.32 g of BTEAC were dissolved in 150.2 g of PM, and reacted at 110 ° C for 16 hours to obtain a vertically aligned polymer (solid content concentration: 30% by mass) (P4). The epoxy valence of the obtained vertically aligned polymer was measured, and it was confirmed that the epoxy group which partially reacts LAUA disappeared.
使EHPE-3150 50.0g、LAUA 5.59g、BTEAC 0.036g溶解於PM 129.8g中,在110℃反應16小時,藉此獲得垂直配向聚合物(固體成分濃度30質量%)(P5)。測定所得垂直配向聚合物之環氧價,確認使LAUA完全反應之部分的環氧基消失。 EHPE-3150 50.0 g, LAUA 5.59 g, and BTEAC 0.036 g were dissolved in PM 129.8 g, and reacted at 110 ° C for 16 hours to obtain a vertical alignment polymer (solid content concentration: 30% by mass) (P5). The epoxy valence of the obtained vertically aligned polymer was measured, and it was confirmed that the epoxy group which partially reacts LAUA disappeared.
使BMAA 25.0g、作為聚合觸媒之AIBN 1.04g溶解於PM 48.4g中,在85℃反應20小時,藉此獲得丙烯酸共聚物溶液(固體成分濃度35質量%)(P6)。所得丙烯酸共聚物之Mn為4,800,Mw為3,100。 25.0 g of BMAA and 1.04 g of AIBN as a polymerization catalyst were dissolved in 48.4 g of PM, and reacted at 85 ° C for 20 hours to obtain an acrylic copolymer solution (solid content concentration: 35 mass%) (P6). The obtained acrylic copolymer had an Mn of 4,800 and a Mw of 3,100.
使EHPE-3150 50.0g、5CCA 24.4g、BTEAC 0.49g溶解於PM 174.7g中,在110℃反應16小時,藉此獲得垂直配向聚合物(固體成分濃度30質量%)(P7)。測定所得垂直配向聚合物之環氧價,確認使5CCA完全反應之部分的環氧基消失。 EHPE-3150 50.0 g, 5 CCA 24.4 g, and BTEAC 0.49 g were dissolved in PM 174.7 g, and reacted at 110 ° C for 16 hours, thereby obtaining a vertical alignment polymer (solid content concentration: 30% by mass) (P7). The epoxy valence of the obtained vertically-oriented polymer was measured, and it was confirmed that the epoxy group which partially reacts 5CCA disappears.
以表1所示之組成調製實施例1至7及比較例1及2之各硬化膜形成組成物,針對各例進行垂直配向性之評價。 The cured film formation compositions of Examples 1 to 7 and Comparative Examples 1 and 2 were prepared in the compositions shown in Table 1, and the vertical alignment properties were evaluated for each of the examples.
使用旋轉塗佈器,以2000轉將實施例及比較例之各硬化膜形成組成物塗佈於無鹼玻璃上30秒。同樣地使用棒塗佈器以濕膜厚4μm將實施例及比較例之各硬化膜形成組成物塗佈於PET膜上。隨後,分別在溫度100℃下,於熱循環式烘箱中進行加熱乾燥60秒,於玻璃上及PET膜上形成各硬化膜。 Each of the cured film forming compositions of the examples and the comparative examples was applied onto an alkali-free glass at 2000 rpm for 30 seconds using a spin coater. Similarly, each of the cured film forming compositions of the examples and the comparative examples was applied onto a PET film with a wet film thickness of 4 μm using a bar coater. Subsequently, heat drying was carried out in a heat cycle oven at a temperature of 100 ° C for 60 seconds to form respective cured films on the glass and on the PET film.
使用棒塗佈器,以濕膜厚6μm將Merck(股)製之垂直配向用聚合性液晶溶液RMS03-015塗佈於該硬化膜 上,在室溫23℃下放置60秒。以300mJ/cm2使該基板上之塗膜曝光,製作相位差材。又,將上述聚合性液晶溶液直接塗佈於玻璃上及PET膜上(以硬化膜形成組成物形成硬化膜),以相同順序製作之相位差材作為比較例3。 Using a bar coater, a vertical alignment of a Merck (manufactured by Merck) was applied to the cured film by a polymerizable liquid crystal solution RMS03-015 at a wet film thickness of 6 μm, and allowed to stand at room temperature at 23 ° C for 60 seconds. The coating film on the substrate was exposed at 300 mJ/cm 2 to prepare a phase difference material. Further, the polymerizable liquid crystal solution was directly applied onto a glass and a PET film (the cured film was formed into a cured film by a cured film), and a phase difference material produced in the same order was used as Comparative Example 3.
使用大塚電子(股)製之相位差測定裝置RETS100測定所製作之相位差材之面內相位差之入射角度依存性。於入射角度0度之面內相位差值為0,於入射角度±50度之面內相位差為38±5nm之範圍者判斷為垂直配向。所得結果示於表2。 The incident angle dependence of the in-plane phase difference of the produced phase difference material was measured using a phase difference measuring device RETS100 manufactured by Otsuka Electronics Co., Ltd. The in-plane phase difference value at the incident angle of 0 degrees is 0, and the vertical phase is judged when the phase difference of the incident angle of ±50 degrees is 38±5 nm. The results obtained are shown in Table 2.
使用棒塗佈器,以濕膜厚4μm將實施例及比較例之各硬化膜形成組成物塗佈於PET膜上。隨後,在溫度100℃以熱循環式烘箱進行加熱乾燥60秒,於PET膜上形成硬化膜。 Each of the cured film forming compositions of the examples and the comparative examples was applied onto a PET film with a wet film thickness of 4 μm using a bar coater. Subsequently, heat drying was performed in a heat cycle oven at a temperature of 100 ° C for 60 seconds to form a cured film on the PET film.
使用棒塗佈器,以濕膜厚6μm將Merck(股)製之垂直配向用聚合性液晶溶液RMS03-015塗佈於該硬化膜上,在室溫23℃放置60秒。以300mJ/cm2使該基板上之塗膜曝光,製作相位差材。又,將上述聚合性液晶溶液直接塗佈於PET膜上(以硬化膜形成組成物形成硬化膜),以相同順序製作之相位差材作為比較例3。 Using a bar coater, a vertical alignment of a Merck (manufactured by Merck) was applied to the cured film by a polymerizable liquid crystal solution RMS03-015 at a wet film thickness of 6 μm, and left at room temperature for 23 seconds at 23 ° C. The coating film on the substrate was exposed at 300 mJ/cm 2 to prepare a phase difference material. Further, the polymerizable liquid crystal solution was directly applied onto a PET film (the cured film was formed into a cured film by a cured film), and a phase difference material produced in the same order was used as Comparative Example 3.
以目視觀察該相位差材,沒有因液晶之不沾著而發生針孔者判斷液晶塗佈性良好。 When the phase difference material was visually observed, it was judged that the liquid crystal coating property was good without causing pinholes due to the non-sticking of the liquid crystal.
所得結果示於表2。 The results obtained are shown in Table 2.
如表2所示,使用由實施例1至7之硬化膜形成組成物所得之硬化膜作為配向材之相位差材,不因使用基材而異,均顯示良好的垂直配向性,且液晶之塗佈性亦良好。 As shown in Table 2, the cured film obtained by forming the composition of the cured films of Examples 1 to 7 as the phase difference material of the alignment material did not differ depending on the use of the substrate, and both exhibited good vertical alignment, and liquid crystal The coatability is also good.
另一方面,使用由不含交聯劑(B)及酸觸媒(C)之任一者之比較例1之硬化膜形成組成物所得之硬化膜作為配向劑之相位差材,以及使用由使用不含垂直配向性基之成分(A)之比較例2之硬化膜形成組成物所得之硬化膜作為配向材之相位差材均無法獲得垂直配向性。 On the other hand, a cured film obtained by forming a composition of the cured film of Comparative Example 1 containing no one of the crosslinking agent (B) and the acid catalyst (C) is used as a phase difference material of the alignment agent, and The cured film obtained by using the cured film of Comparative Example 2 containing no component (A) of the vertical alignment group as the phase difference material of the alignment material could not obtain vertical alignment.
此外,未形成硬化膜而得之比較例3之相位差材雖在 玻璃上顯示垂直配向性,但PET上未顯示垂直配向性。 Further, the phase difference material of Comparative Example 3 obtained without forming a cured film was Vertical alignment is shown on the glass, but vertical alignment is not shown on the PET.
本發明之硬化膜形成組成物作為形成液晶顯示元件之液晶配向膜、或用於形成設置於液晶顯示元件之內部或外部之光學異向性膜之配向材之材料非常有用,尤其適合作為IPS-LCD之光學補償膜之材料。 The cured film forming composition of the present invention is useful as a liquid crystal alignment film for forming a liquid crystal display element, or a material for forming an alignment material of an optical anisotropic film provided inside or outside the liquid crystal display element, and is particularly suitable as an IPS- The material of the optical compensation film of LCD.
Claims (7)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013178446 | 2013-08-29 | ||
JP2013-178446 | 2013-08-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201522484A TW201522484A (en) | 2015-06-16 |
TWI653285B true TWI653285B (en) | 2019-03-11 |
Family
ID=52586559
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107124333A TWI653287B (en) | 2013-08-29 | 2014-08-29 | Cured film forming composition, alignment material and retardation material |
TW103129881A TWI653285B (en) | 2013-08-29 | 2014-08-29 | Cured film forming composition, alignment material and retardation material |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107124333A TWI653287B (en) | 2013-08-29 | 2014-08-29 | Cured film forming composition, alignment material and retardation material |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP6460340B2 (en) |
KR (1) | KR102193060B1 (en) |
CN (1) | CN105474083B (en) |
TW (2) | TWI653287B (en) |
WO (1) | WO2015030004A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018155581A1 (en) * | 2017-02-22 | 2018-08-30 | 日産化学株式会社 | Cured film-forming composition, alignment material, and phase difference material |
WO2024070691A1 (en) * | 2022-09-28 | 2024-04-04 | 富士フイルム株式会社 | Laminate, image display device, optical device, and head-mounted display |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012020798A1 (en) | 2010-08-11 | 2012-02-16 | 日産化学工業株式会社 | Resin composition, liquid crystal orientation material, and phase difference material |
TW201213397A (en) | 2010-07-15 | 2012-04-01 | Jsr Corp | Liquid crystal alignment agent for phase difference film, and liquid crystal alignment film for phase difference film, and phase difference film and producing method thereof |
WO2013054784A1 (en) | 2011-10-11 | 2013-04-18 | 日産化学工業株式会社 | Cured film formation composition, orientation material, and phase difference material |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2857889B2 (en) | 1988-11-04 | 1999-02-17 | 富士写真フイルム株式会社 | Liquid crystal display |
US5693691A (en) * | 1995-08-21 | 1997-12-02 | Brewer Science, Inc. | Thermosetting anti-reflective coatings compositions |
JP3204182B2 (en) | 1997-10-24 | 2001-09-04 | 日本電気株式会社 | In-plane switching LCD |
JP2001281669A (en) | 2000-03-30 | 2001-10-10 | Matsushita Electric Ind Co Ltd | Liquid crystal alignment layer, its manufacturing method and liquid crystal display device and its manufacturing method |
JP2002333717A (en) * | 2001-05-07 | 2002-11-22 | Nissan Chem Ind Ltd | Antireflection film forming composition for lithography |
KR100677050B1 (en) | 2003-10-22 | 2007-01-31 | 주식회사 엘지화학 | In-plane switching liquid crystal display comprising compensation film for angular field of view using +a-plate and +c-plate |
JP4458306B2 (en) * | 2007-08-21 | 2010-04-28 | Jsr株式会社 | Liquid crystal aligning agent, method for producing liquid crystal aligning film, and liquid crystal display element |
JP5233526B2 (en) * | 2008-09-05 | 2013-07-10 | 東レ株式会社 | Photosensitive composition, cured film formed therefrom, and device having cured film |
JP5454772B2 (en) * | 2008-11-17 | 2014-03-26 | Jsr株式会社 | Liquid crystal aligning agent, liquid crystal aligning film, method for forming the same, and liquid crystal display element |
-
2014
- 2014-08-26 JP JP2015534237A patent/JP6460340B2/en active Active
- 2014-08-26 KR KR1020167005250A patent/KR102193060B1/en active IP Right Grant
- 2014-08-26 WO PCT/JP2014/072320 patent/WO2015030004A1/en active Application Filing
- 2014-08-26 CN CN201480046361.8A patent/CN105474083B/en active Active
- 2014-08-29 TW TW107124333A patent/TWI653287B/en active
- 2014-08-29 TW TW103129881A patent/TWI653285B/en active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201213397A (en) | 2010-07-15 | 2012-04-01 | Jsr Corp | Liquid crystal alignment agent for phase difference film, and liquid crystal alignment film for phase difference film, and phase difference film and producing method thereof |
WO2012020798A1 (en) | 2010-08-11 | 2012-02-16 | 日産化学工業株式会社 | Resin composition, liquid crystal orientation material, and phase difference material |
WO2013054784A1 (en) | 2011-10-11 | 2013-04-18 | 日産化学工業株式会社 | Cured film formation composition, orientation material, and phase difference material |
Also Published As
Publication number | Publication date |
---|---|
TWI653287B (en) | 2019-03-11 |
KR102193060B1 (en) | 2020-12-18 |
KR20160052545A (en) | 2016-05-12 |
CN105474083A (en) | 2016-04-06 |
CN105474083B (en) | 2019-10-08 |
TW201522484A (en) | 2015-06-16 |
JPWO2015030004A1 (en) | 2017-03-02 |
WO2015030004A1 (en) | 2015-03-05 |
TW201839048A (en) | 2018-11-01 |
JP6460340B2 (en) | 2019-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9823401B2 (en) | Cured film formation composition, orientation material, and retardation material | |
EP2557119B1 (en) | Composition forming heat-cured film having photo-alignment properties | |
JP5713213B2 (en) | Thermosetting film forming composition having photo-alignment property | |
TWI673290B (en) | Cured film forming composition, alignment material and retardation material | |
TWI644961B (en) | Cured film forming composition, alignment material and retardation material | |
TW201116570A (en) | Thermoset film forming composition having photo-alignment | |
TWI636069B (en) | Thermosetting composition having photoalignment properties, alignment layer, substrate with alignment layer, retardation plate, and device | |
TW201529669A (en) | Cured film forming composition, alignment material and retardation material | |
CN107532006B (en) | Thermosetting resin composition and vertically aligned retardation film | |
TW201627389A (en) | Cured film forming composition, alignment material and retardation material | |
TWI653285B (en) | Cured film forming composition, alignment material and retardation material | |
CN107207641B (en) | Composition for forming cured film, alignment material, and phase difference material | |
JP7365003B2 (en) | Cured film forming composition, alignment material and retardation material | |
TWI807068B (en) | Cured film, alignment material and retardation material | |
TW202146566A (en) | Cured film-forming composition, alignment material, and phase difference material | |
WO2020184463A1 (en) | Liquid crystal alignment agent for photoalignment, alignment material, and phase difference material |